



Immunotech Biopharm Ltd  
永泰生物製藥有限公司

*(incorporated in the Cayman Islands with limited liability)*

Stock Code: 6978

2024

INTERIM REPORT

# Content

Corporate Information	2
Financial and Operational Data Highlights	4
Corporate Profile	5
Management Discussion and Analysis	6
Other Information	20
Report on Review of Condensed Consolidated Financial Statements	33
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income	35
Condensed Consolidated Statement of Financial Position	36
Condensed Consolidated Statement of Changes in Equity	38
Condensed Consolidated Statement of Cash Flows	39
Notes to the Condensed Consolidated Financial Statements	40
Definitions and Glossary of Technical Terms	58



# Corporate Information

## BOARD OF DIRECTORS

### Executive Directors

Mr. TAN Zheng (*Chairman*)  
Dr. WANG Yu (*CEO and CTO*)

### Non-executive Directors

Mr. TAO Ran  
Mr. WANG Ruihua  
Mr. YANG Fan  
Mr. WANG Donghu

### Independent non-executive Directors

Professor WANG Yingdian  
Mr. NG Chi Kit  
Ms. PENG Sujiu

## JOINT COMPANY SECRETARIES

Mr. YANG Ning (resigned on 26 July 2024)  
Mr. CHEN Ran (appointed on 26 July 2024)  
Ms. LEUNG Shui Bing (appointed on 26 July 2024)

## AUTHORISED REPRESENTATIVES

Mr. TAN Zheng  
Mr. YANG Ning (resigned on 26 July 2024)  
Mr. CHEN Ran (appointed on 26 July 2024)

## AUDIT COMMITTEE

Mr. NG Chi Kit (*Chairman*)  
Mr. TAO Ran  
Professor WANG Yingdian

## REMUNERATION COMMITTEE

Professor WANG Yingdian (*Chairman*)  
Ms. PENG Sujiu  
Mr. NG Chi Kit

## NOMINATION COMMITTEE

Mr. TAN Zheng (*Chairman*)  
Ms. PENG Sujiu  
Professor WANG Yingdian

## AUDITORS

Deloitte Touche Tohmatsu  
*Registered Public Interest Entity Auditors*  
35/F, One Pacific Place  
88 Queensway  
Hong Kong

## LEGAL ADVISERS

*As to Hong Kong law*  
Eric Chow & Co. in Association with  
Commerce & Finance Law Offices  
3401, Alexandra House  
18 Chater Road, Central  
Hong Kong

# Corporate Information

## PRINCIPAL BANKS

China Construction Bank,  
Beijing Branch, BDA Sub-Branch  
Building 55  
2 Jingyuan North Street  
BDA  
Beijing, the PRC

Bank of Communications,  
Hong Kong Branch  
16/F, Lee Garden Five  
18 Hysan Avenue  
Causeway Bay  
Hong Kong

China CITIC Bank,  
Beijing Branch, Xinxing Sub-Branch  
Xinxing Hotel  
17 Middle West Third Ring Road  
Haidian District  
Beijing, the PRC

## HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN THE PRC

8/F, Block 1  
Guosheng Technology Park  
1 Kangding Street  
BDA  
Beijing, the PRC

## PRINCIPAL PLACE OF BUSINESS IN HONG KONG

31/F, Tower Two, Times Square  
1 Matheson Street  
Causeway Bay  
Hong Kong

## REGISTERED OFFICE

P.O. Box 309  
Ugland House  
Grand Cayman KY1-1104  
Cayman Islands

## PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE

Maples Fund Services (Cayman) Limited  
P.O. Box 1093, Boundary Hall  
Cricket Square  
Grand Cayman, KY1-1102  
Cayman Islands

## HONG KONG SHARE REGISTRAR

Computershare Hong Kong Investor Services Limited  
Shops 1712-1716, 17th Floor  
Hopewell Centre  
183 Queen's Road East  
Wanchai  
Hong Kong

## STOCK CODE

6978

## COMPANY'S WEBSITE

[www.eaal.net](http://www.eaal.net)

## DATE OF LISTING

10 July 2020

# Financial and Operational Data Highlights

## HIGHLIGHTS FOR THE SIX MONTHS ENDED 30 JUNE 2024

	For the six months ended 30 June		
	2024 RMB'000 (unaudited)	2023 RMB'000 (unaudited)	Change (%)
Other income	<b>6,526</b>	5,533	17.9
Other gains and losses, net	<b>19,836</b>	(20,269)	(197.9)
Administrative expenses	<b>(23,048)</b>	(25,035)	(7.9)
Research and development expenses	<b>(91,118)</b>	(74,315)	22.6
Finance costs	<b>(3,851)</b>	(4,372)	(11.9)
Other expenses	<b>(901)</b>	(144)	525.7
Loss before tax	<b>(92,556)</b>	(118,602)	(22.0)
Income tax expense	–	–	–
Loss and total comprehensive expense for the period	<b>(92,556)</b>	(118,602)	(22.0)
Loss and total comprehensive expense for the period attributable to:			
Owners of the Company	<b>(92,515)</b>	(118,114)	(21.7)
Non-controlling interests	<b>(41)</b>	(488)	(91.6)
	<b>(92,556)</b>	(118,602)	
Loss per share	<b>RMB</b>	RMB	
– Basic	<b>(0.18)</b>	(0.23)	
– Diluted	<b>(0.18)</b>	(0.23)	

	As at 30 June 2024		
	RMB'000 (unaudited)	As at 31 December 2023 RMB'000 (audited) (restated)	Change (%)
Non-current assets	<b>538,889</b>	632,390	(14.8)
Current assets	<b>180,830</b>	213,894	(15.5)
Current liabilities	<b>(478,206)</b>	(530,275)	(9.8)
Net current liabilities	<b>(297,376)</b>	(316,381)	(6.0)
Non-current liabilities	<b>(163,179)</b>	(145,119)	12.4
Net assets	<b>78,334</b>	170,890	(54.2)



# Corporate Profile

## OVERVIEW

The Group is a leading cellular immunotherapy biopharmaceutical company in China focusing on the research, development, and commercialisation of T cell immunotherapy for almost 18 years. EAL<sup>®</sup> – its Core Product Candidate – is a multi-target cellular immunotherapy product with more than a decade of track record of clinical application and has shown efficacy in the treatment of various types of cancer. EAL<sup>®</sup>-related research began in 2006, and the Group has improved upon its cell culture system and methods, and developed its proprietary, patented technology platform for the production of EAL<sup>®</sup> cells.

The Group has selected the prevention of postsurgical recurrence of liver cancer as the clinical indication for the clinical trial of EAL<sup>®</sup>. It plans to submit the application for the commercialisation of EAL<sup>®</sup> in the PRC market after achieving statistically significant result for its clinical trials.

The Group's product pipeline features major classes of cellular immunotherapy products, including both non- genetically-modified and genetically-modified products, as well as both multi-target and single-target products. Other than EAL<sup>®</sup>, the main product candidates of the Group include 6B11, the CAR-T cell series and the TCR-T cell series.

Composed of experienced cancer immunologists, the core technology team is equipped with industry foresight and sensitivity. The R&D organisational structure encompasses early research, pre-clinical studies, clinical studies, and commercialised production and management, allowing for rapid implementation of the product R&D efforts.

The Group has also established technology platforms necessary for the R&D of cellular immunotherapy products and in place an organisational and management platform for clinical trials.

# Management Discussion and Analysis

## BUSINESS REVIEW

### R&D of the product candidates

The following chart summarises the product candidates and their R&D status as at the date of this interim report:

Product Categories	Product Code	Therapeutic Area	Indications	Early Research	Pre-clinical Studies	IND	Clinical Stage		NDA
							Clinical Phase I	Clinical Phase II	
Non-genetically Modified Products	EAL®	Solid Tumours	Liver cancer after surgery	[Progress bar: ~90%]					
	6B11		Platinum resistant ovarian cancer (OC)	[Progress bar: ~60%]					
Genetically Modified Products	CAR-T	Hematologic Malignancies	Relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) under 25 years of age	[Progress bar: ~85%]					
			Denocabtagene Ciltoluceel Injection	Relapsed or refractory diffuse large B-cell lymphoma	[Progress bar: ~75%]				
	TCR-T	Post-transplantation Infections	CMV infection after hematopoietic stem cell transplantation	[Progress bar: ~50%]					
			TCR-T-HBV	Solid Tumours	[Progress bar: ~40%]				
	VAC	Hematologic Malignancies	Sequential CD19 CAR-T for relapsed or refractory B hematologic malignancies	[Progress bar: ~70%]					

**Cautionary statement required by Rule 18A.08(3) of the Listing Rules: The Company may not be able to ultimately develop and market its product candidates (including its Core Product Candidate) successfully.**

### Non-genetically modified cell product pipeline

#### EAL®

EAL® is a multi-target cellular immunotherapy product with more than a decade of track record of clinical application in the treatment of cancer. It is a preparation of activated and expanded T cells originally taken from a patient's autologous peripheral blood and cultured using the patented methods. The main active component of the product is CD8<sup>+</sup> cytotoxic T cells, and its surface marker is the CD3 molecule.

EAL® is undergoing Phase II clinical trial with the postsurgical recurrence of liver cancer selected as the clinical indication. Based on the Group's communications with the CDE, the Group may apply for marketing approval for EAL® indicated for the prevention of postsurgical recurrence of liver cancer using the interim results of the ongoing clinical trial or the final results at the end of the clinical trial if such results are statistically significant. The Group may further communicate with the CDE to facilitate the assessment after obtaining clinical trial results that support the efficacy of EAL®. In September 2023, EAL® was granted breakthrough therapy designation for the prevention of postsurgical recurrence of liver cancer by the CDE. The designation was granted based on the solid clinical efficacy and safety data of EAL®. Drug candidates with breakthrough therapy designation may be considered for conditional approval and priority review when submitting a new drug application. According to the CDE, the breakthrough therapy designation provides opportunities for more intensive CDE guidance and discussion with respect to clinical trials and development strategy, and for priority review later. Accordingly, it is expected that the clinical development of EAL® would be expedited, which should accelerate its early access to the patients.

# Management Discussion and Analysis

As at the date of this interim report, the Group has completed the enrolment of 430 targeted patients for the Phase II clinical trial. The Group is confident that it could submit the NDA for the product to the NMPA in the second half of 2024 and hopefully launch the product in 2025.

## **6B11-OCIK Injection**

6B11-OCIK Injection is an injection of ovarian cancer autologous cytotoxic T Lymphocyte. 6B11 is the monoclonal anti-idiotypic antibody prepared by Beijing Weixiao with COC166-9 immunised mice with monoclonal antibody to mimic ovarian cancer-related antigen OC166-9. The use of 6B11 can induce specific anti-ovarian cancer humoral and cellular immune antibodies in vitro, which can be cultured and proliferated in vitro (6B11-OCIK Injection) and infused back to the subject to achieve the purpose of specifically killing tumour cells.

As at the date of this interim report, the Group has completed the enrolment of six targeted patients for the Phase I clinical trial for 6B11-OCIK Injection and has completed the preliminary analysis and the interim results of the ongoing clinical trial. The Group will conduct the Phase II clinical trials at the appropriate time according to operational arrangements.

## **Genetically modified cell product pipeline**

### **CAR-T cell product pipeline**

#### *CAR-T-19 Injection*

The CAR-T-19 series forms the core of the CAR-T cell product pipeline. CAR-T-19 Injection is indicated for the treatment of pediatric and young adult patients up to and including the age of 25 with B-ALL. The CAR-T-19 Injection product candidate has shown efficacy in a clinical study, and the IND application for the product candidate with B-ALL as the clinical indication was accepted for processing by the CDE in August 2019.

In December 2020, the Group received an approval of the IND for clinical trials of CAR-T-19 Injection from the CDE. Following the IND approval, the Group has commenced Phase I clinical trial process for the CAR-T-19 Injection and presented the Phase I clinical trial protocol and proposed timetable in a kick-off conference meeting, which took place in Beijing, the PRC on 25 February 2021. In October 2023, the Group applied to the CDE for the commencement of the Phase II clinical trial work.

As at the date of this interim report, the Group has completed the enrolment of 25 targeted patients for the Phase II clinical trial for CAR-T-19 Injection. It is expected that the targeted patients enrolment would be completed and the preliminary analysis and results would be published in the first half of 2026.

#### *Denocabtagene Ciloleucel Injection*

Denocabtagene Ciloleucel Injection, originally known as RC19D2, CAR-T-19-D2 and CART-19-DNR, targets immunosuppressive molecule TGF- $\beta$ , is an injection for the treatment of patients with relapsed and refractory diffuse large B-cell lymphoma. The injection has the goal of overcoming CAR-T cells' pain points in terms of the lack of persistence, the lack of efficacy in the treatment of solid tumours, and in the prevention of tumour recurrence. In March 2023, the Group has obtained the clinical approval for the Denocabtagene Ciloleucel Injection from the NMPA.



## Management Discussion and Analysis

As at the date of this interim report, the Group has completed the enrolment of eight targeted patients for the Phase I clinical trial for the Denocabtagene Ciloleucel Injection. It is expected that the targeted patients enrolment would be completed in the year end of 2024 and the preliminary analysis and results would be published in the first half of 2025.

### *aT19 Injection*

The active component of the aT19 Injection product candidate is autologous or after stem cell transplantation T cells genetically modified to express CD19. The gene introduced therein is an encoded gene structure that can express human CD19 protein. The reinfusion of the aT19 Injection after injecting the CAR-T-19 Injection has the potential to reactivate CAR-T cells, restart the proliferation of CAR-T cells, and induce more immune memory cells, thereby increasing the chance of killing trace amounts of residual CD19-positive tumour cells and of preventing recurrence. Through multiple stimulations from CD19 antigen, the number of CAR-T cells with immune memory function may also increase, thereby prolonging the immune surveillance duration of CAR-T cells and reducing the probability of recurrence of CD19-positive tumours.

As at the date of this interim report, the Group has received an approval of the IND for the Phase I clinical trial from the CDE for the aT19 Injection in February 2024. The Group will conduct the Phase I clinical trials at the appropriate time according to operational arrangements.

Based on the technology of the CAR-T-19 Injection, the Denocabtagene Ciloleucel Injection and aT19 Injection product candidates have the ultimate goal of overcoming CAR-T cells' pain points in terms of the lack of persistence, the lack of efficacy in the treatment of solid tumours, and in the prevention of tumour recurrence. If verified, the technology underlying these two product candidates may be used in the genetic modification of other CAR-T and TCR-T cell products targeting solid tumours.

### ***TCR-T cell product pipeline***

TCR-T cell therapy is an immunotherapy based on the reinfusion of tumour antigen-specific T cells. The Group established single-cell sequencing-based technology platform to obtain different HLA-restricted TCR coding sequences for specific antigens. Subsequently, the TCR genes are inserted into the self-constructed lentiviral vector for transduction into T cells, and then the killing effect on tumour cells is confirmed by an *in vitro* and *in vivo* model. In this way, the Group intends to finally prepare a gene database for TCRs where different antigenic specificities presented by common HLA could be recognised.

To overcome the immunosuppressive mechanisms of tumours, the Group has constructed expression vectors that co-express TCR and CXCR3, IL-12, or TGF- $\beta$  DNR, and it plans to use transplanted tumour models to investigate their effects on the therapeutic effect of TCR-T cells, thereby laying the foundation for the development of the next generation of TCR-T cell products for the treatment of solid tumours.

The Group has a number of TCR-T cell product candidates under pre-clinical studies, with the relevant target antigens including the HERV-E antigen expressed in clear cell renal cell carcinoma, and antigens derived from viruses such as CMV and HBV.

# Management Discussion and Analysis

In January 2021, the Company entered into a license agreement with T-Cure, an independent third party, granting the Company an exclusive license to use its patent rights and technology for the development, manufacturing and commercialisation of licensed products in certain territories in the field of immunotherapy for renal cell carcinoma. The transfer of the relevant technologies agreed upon in the agreement was completed in March 2022. During the Reporting Period, the license agreement was terminated, the Group did not plan to continue the development activities in relation to such licensed technology.

**Cautionary statement required by Rule 18A.08(3) of the Listing Rules: the Company cannot guarantee that the Core Product Candidate and other product candidates will ultimately be successfully developed and marketed.**

## The Group's facilities

The Group has a total area of approximately 27,604 sq.m. for a R&D and manufacturing centre in Beijing, the PRC, which includes a quality inspection building and clean laboratory. Such facilities are capable of supporting our pre-clinical and clinical R&D of cellular immunotherapy product candidates, as well as the early production needs upon marketing approval for the product candidates. All these facilities have been issued clean facility (area) inspection reports by the Beijing Institute for Drug Control. Leadman manufacturing shop and the Guosheng Laboratory in Beijing have the capacity to handle approximately 40,000 samples per year, and can satisfy the needs from the clinical trials for its product pipeline for two to three years, as well as the early production needs from the commercialisation of EAL®.

In order to expedite the clinical trials and prepare for the future commercialisation roadmap, the Group is planning to establish R&D and production centres in densely-populated areas in China in view of the six-hours transportation radius for EAL®; namely:

- Northern China region:
  - On 17 June 2021, the commencement ceremony for the construction of the R&D and industrialisation base took place, which marked the official launch of the construction project of the Group's R&D and industrialisation base in Beijing, the PRC. The expected investment for the Beijing production centre would amount to approximately RMB1.2 billion, which is expected to be financed by a bank loan. After completion, the Beijing production centre is expected to reach an annual production capacity of over 200,000 batches of cells, covering the domestic Northern and Northeast markets in China.

# Management Discussion and Analysis

- Eastern China region:
  - In February 2021, Beijing Yongtai, entered into a cooperation framework agreement with the Shaoxing Binhai New Area Management Committee\* (紹興濱海新區管理委員會) in relation to, among others, establishing the proposed production centre of EAL® for the Eastern China region, the proposed joint establishment of academician workstations with universities and research institutions in the PRC, the proposed land development regarding the project and the proposed establishment of the Industry Fund, targeted at investments in the upstream and downstream industrial chain of, among other things, cellular immunotherapy. At present, the total investment for the project is expected to be approximately RMB1.0 billion. The first phase of construction of proposed production centre of EAL® for the Eastern China region is expected to complete within 60 months after obtaining the relevant land title certificate. As at the date of this interim report, the Group has commenced the construction of the production centre in Shaoxing.
  - On 11 May 2022, Shanghai Yongtai Immunobiological Products Co Ltd (上海永泰免疫生物製品有限公司) as the lessee, entered into a land use rights grant contract with Shanghai Songjiang Bureau of Planning and Natural Resources\* (上海市松江區規劃和自然資源局) as the lessor, in relation to lease a land located in Shanghai Songjiang Industrial Area, the PRC, with a total site area of approximately 21,848.6 sq.m. (the “**Land**”). The Land is for industrial use and the term of the land use rights for the Land is 20 years from the delivery date of the Land. The Company intends to use the land for R&D centre of the product candidates in the Eastern China region.

## Quality assurance

The Group has formulated its quality management documentation in accordance with GMP, covering production process procedures, product quality standards, equipment and facilities operation procedures, inspection procedures, sample retention and sampling management procedures, personnel training, environmental monitoring, verification and confirmation, deviation inspection, and quality risk control management procedures. The Group has standardised the selection, purchase, inspection, release, production process, inspection process, product storage, and transportation of the materials used in the products to ensure full compliance with relevant laws and regulations and GMP requirements. Under the Group's quality management procedures, final products can be released only after quality inspection, in order to ensure that the products meet the relevant standards and intended use.

In particular, the production of EAL® and CAR-T-19 Injection have achieved standardisation. The Group has developed comprehensive standards in relation to the production process in order to ensure that the product is of consistent quality.

To ensure that the final products meet quality standards, all quality issues during the production process are documented, escalated to, and reviewed by senior management. The Group also conducts a formal risk assessment and justification in accordance with the standards and procedures under the quality management system and policies.

The head of the quality department reports directly to the CEO. There are two sub-teams within the quality department and they are responsible for quality assurance and quality control respectively. As at 30 June 2024, the Company had 45 staff members in the quality department.

# Management Discussion and Analysis

## Future and outlook

### ***Expedite the clinical trial and prepare for commercialisation of EAL®***

The Group plans to fully promote the application, production and quality verification of the Phase II clinical trial of EAL®, with a view to accelerating registration and data collection, while preparing for future commercialisation.

Cellular immunotherapy products are subject to diminishing cell activity once taken out of the laboratory. As at the date of this interim report, the Company confirmed the sites in Beijing, Shaoxing and Shanghai to construct production centres. The Company is planning to further establish R&D and production centres in densely-populated areas in the PRC in view of the six-hours transportation radius for EAL®. After establishing its presence in Beijing, Shaoxing and Shanghai, the Company plans to build production centres in other major cities such as Guangzhou and Chengdu.

The first patient for the Phase II clinical trial for EAL® was enrolled in September 2018, and as at the date of this interim report, the Group has completed the enrolment of 430 targeted patients for the Phase II clinical trial. The Group is confident that it could submit the NDA for the product to the NMPA in the second half of 2024 and hopefully will launch the product in 2025.

### ***Advance the pre-clinical studies for pipeline products, and accelerate their entry into clinical trials***

The Group plans to continue to invest into its CAR-T and TCR-T cell product pipelines. In particular, in March 2023, the Group has obtained the clinical approval for the Denocabtagene Ciloleucel Injection from the NMPA. In February 2024, the Group has also obtained the clinical approval for the aT19 Injection from the NMPA.

Patients often suffer from viral infections after hematopoietic stem cell transplantation/solid organ transplant. CMV infection is a major cause of morbidity and mortality among those patients and is one of the most common risk factors. By genetically transducing general T cells with TCR genes that specifically recognise CMV-associated antigens, there is a potential for the treatment of CMV infection-related malignancies. The first product candidate in this category is the TCR-T-CMV, which is targeted to enter its clinical trial in 2025.

# Management Discussion and Analysis

## ***Enhance the technology platform and strengthen the product pipeline***

The Company is committed to continuing its studies in cellular immunotherapy products appropriate for different tumour types and stages with improved efficacy compared to currently-available products.

In the area of neoantigens formed from tumour mutations in solid tumours, the Company intends to identify antigen – specific TCRs suitable for different individuals, with a view to ultimately constructing a gene database for TCRs targeting of tumour neoantigens in an effort to conduct research into molecule-specific TCR-T cell products for the treatment of solid tumours. In the area of malignant disease caused by viruses such as CMV and HBV, the Group is conducting research into TCR-T cell products targeting at cells expressing virus antigens.

## ***Develop viral vector production and early-stage R&D services business***

The Company has established the viral vector production system, which meets the pharmaceutical production quality standards under GMP requirements. The viral vectors that the Company has produced meet the requirements for biological products and can be produced in scale. At present, domestic CAR-T cells companies often order viral vectors from abroad.

Due to the high degrees of individualisation and the nature of biological active products, cellular immunotherapy products are subject to R&D carried out through a systematic technology platform covering cell preparation, cell quality control, cell potency studies, cell safety studies, etc. In the absence of such platform, the productization of the cells would be difficult. The Group began to carry out CDMO business during the Reporting Period, based on the systematic technology platform established by the Group for the R&D of cellular immunotherapy products, and it can provide customised services according to the needs of customers.

## ***Expand strategic collaboration and explore acquisition opportunities on the basis of organic growth***

Based on endogenous growth, the Company plans to expand strategic collaboration and explore acquisition opportunities to seek the sale, technology transfer and strategic cooperation of existing and research products. The Company will also continue to seek new potential directions for the development of cellular immunotherapy products and explore opportunities for mergers and acquisitions and strategic cooperation.

# Management Discussion and Analysis

## FINANCIAL REVIEW

The following table summarises the Group's results of operations for the six months ended 30 June 2024 and 2023:

	For the six months ended 30 June			
	2024 RMB'000 (unaudited)	2023 RMB'000 (unaudited)	Change RMB'000	Change (%)
Other income	<b>6,526</b>	5,533	993	17.9
Other gains and losses, net	<b>19,836</b>	(20,269)	40,105	(197.9)
Administrative expenses	<b>(23,048)</b>	(25,035)	1,987	(7.9)
Research and development expenses	<b>(91,118)</b>	(74,315)	(16,803)	22.6
Finance costs	<b>(3,851)</b>	(4,372)	521	(11.9)
Other expenses	<b>(901)</b>	(144)	(757)	525.7
Loss before tax	<b>(92,556)</b>	(118,602)	26,046	(22.0)
Income tax expense	<b>-</b>	-	-	-
Loss and total comprehensive expense for the period	<b>(92,556)</b>	(118,602)	26,046	(22.0)
Loss and total comprehensive expense for the period attributable to:				
Owners of the Company	<b>(92,515)</b>	(118,114)	25,599	(21.7)
Non-controlling interests	<b>(41)</b>	(488)	447	(91.6)
	<b>(92,556)</b>	(118,602)		
Loss per share	<b>RMB</b>	RMB		
– Basic	<b>(0.18)</b>	(0.23)		
– Diluted	<b>(0.18)</b>	(0.23)		



# Management Discussion and Analysis

## Other income

Other income of the Group increased by approximately 17.9% from approximately RMB5.5 million for the six months ended 30 June 2023 to approximately RMB6.5 million for the six months ended 30 June 2024, which was primarily due to the increase in government grants for machinery during the Reporting Period.

Set out below are the components of other income for the periods indicated:

	For the six months ended 30 June	
	2024 RMB'000 (unaudited)	2023 RMB'000 (unaudited)
Income from provision of cell cryopreservation services ( <i>Note</i> )	355	355
Rental income from leasehold land	229	–
Income from technical services	832	–
Interest income on bank balances and deposits	381	1,448
Interest income on financial assets at fair value through other comprehensive income (“ <b>FVTOCI</b> ”)	–	848
Interest income from lease deposits	97	96
Government grants		
– Research and development activities	428	2,617
– Machinery	4,128	66
– Others	76	103
<b>Total</b>	<b>6,526</b>	5,533

Note: Cell cryopreservation is the process whereby cells are preserved by cooling to very low temperatures.

## Other gains and losses, net

The Group recorded other net gains of approximately RMB19.8 million for the six months ended 30 June 2024 as compared to other net losses of approximately RMB20.3 million for the six months ended 30 June 2023. Such turnaround from losses to gains during the Reporting Period was mainly attributable to fair value gain on other financial liabilities during the Reporting Period. For details, please refer to note 6 to the condensed consolidated financial statement for the six months ended 30 June 2024 in this interim report.

The net other gains and losses for the Reporting Period primarily consisted of fair value gain (loss) on other financial liabilities, termination loss of an intangible asset and impairment loss on prepayment to a supplier.

# Management Discussion and Analysis

## Administrative expenses

Administrative expenses of the Group decreased by approximately 7.9% from approximately RMB25.0 million for the six months ended 30 June 2023 to approximately RMB23.0 million for the six months ended 30 June 2024, which was primarily due to the decrease in travel and other expenses.

The Group's administrative expenses primarily include staff costs, professional fees including fees paid to contractors and recruiters, depreciation expenses of the right-of-use assets for the leases, vehicles and office equipment, travel and hospitality fees and others.

## Research and development expenses

Research and development expenses of the Group increased by approximately 22.6% from approximately RMB74.3 million for the six months ended 30 June 2023 to approximately RMB91.1 million for the six months ended 30 June 2024, which was primarily due to the increase in contracting costs during the Reporting Period.

	For the six months ended 30 June	
	2024 RMB'000 (unaudited)	2023 RMB'000 (unaudited)
Cost of materials for research and development project	<b>9,829</b>	6,473
Staff costs	<b>26,431</b>	26,419
Contracting costs	<b>25,664</b>	10,871
Depreciation and amortisation	<b>23,255</b>	20,477
Others	<b>5,939</b>	10,075
<b>Total</b>	<b>91,118</b>	74,315

## Finance costs

Finance costs of the Group decreased by approximately 11.9% from approximately RMB4.4 million for the six months ended 30 June 2023 to approximately RMB3.9 million for the six months ended 30 June 2024, which was primarily due to the decrease in interest expenses on lease liabilities recognised pursuant to IFRS 16.

## Loss before tax

For the above reasons, the loss before tax of the Group decreased by approximately 22.0% from approximately RMB118.6 million for the six months ended 30 June 2023 to approximately RMB92.6 million for the six months ended 30 June 2024.

# Management Discussion and Analysis

## Income tax expense

For the six months ended 30 June 2024, the Company is not subject to any income tax in the Cayman Islands. No Hong Kong profit tax was provided for as there was no estimated assessable profit of our Hong Kong subsidiary, which was subject to Hong Kong profit tax during the Reporting Period. The subsidiaries located in the PRC, were generally subject to the statutory enterprise income tax at a rate of 25% on the assessable profits according to the PRC Enterprise Income Tax Law. Beijing Yongtai, one of the PRC subsidiaries, was accredited as a High And New Technology Enterprise for a three-year period commencing from 31 October 2018 and it was accredited as a High And New Technology Enterprise again for another three-year period on 17 December 2021. Yongtai Ruike, one of the PRC subsidiaries, was also accredited as a High And New Technology Enterprise for a three-year period commencing from 20 December 2023. Accordingly, Beijing Yongtai and Yongtai Ruike enjoyed a lower tax rate of 15% during the Reporting Period.

## Liquidity and capital resources

The bank balances and cash increased by approximately RMB27.5 million from approximately RMB52.2 million as at 31 December 2023 to approximately RMB79.6 million as at 30 June 2024, which was primarily due to the disposal of certificates of deposits.

## INDEBTEDNESS

### Lease liabilities

As at 30 June 2024, the lease liabilities were approximately RMB123.5 million. The lease liabilities were secured by rental deposits and unguaranteed.

### Contingent liabilities, charge of assets and guarantees

In February 2023, the Company completed issuance of the Convertible Bonds. The Convertible Bonds are secured by the security for the Company's payment obligations and the performance of Company's obligations in respect of the Convertible Bonds. The security includes assets mortgage and share mortgages. The assets mortgage includes the mortgage of: (1) a land use right; and (2) other pledged assets including certain equipment and financial assets at FVTPL, of the Group. The share mortgages include the Shares charged by Tan Zheng Ltd and Tan Yue Yue Ltd under the transaction documents, which amounts to 19,285,714 Shares held by Tan Zheng Ltd and 6,714,286 Shares held by Tan Yue Yue Ltd.

Save as disclosed above, the Group did not have any outstanding mortgages, charges, debentures, other issued debt capital, bank overdrafts, loans, borrowings, lease liabilities, liabilities under acceptance or other similar indebtedness, any guarantees or other material contingent liabilities as at 30 June 2024.

# Management Discussion and Analysis

## CAPITAL STRUCTURE

The Shares were listed on the Main Board of the Stock Exchange on 10 July 2020, and 100,000,000 Shares were issued at the offer price of HK\$11.00 per Share by way of Global Offering.

Subsequently, the Company announced that the over-allotment option described in the Prospectus was partially exercised by the joint representatives, on behalf of the international underwriters, on 31 July 2020, in respect of an aggregate of 14,584,000 Shares representing approximately 14.58% of the total number of the Shares initially available under the Global Offering before any exercise of the over-allotment option to facilitate the return to Tan Zheng Ltd of the borrowed Shares under the stock borrowing agreement which were used to cover over-allocations in the international offering. There was no change in the capital structure of the Group since then. The share capital of the Group only comprises ordinary shares. As at 30 June 2024, the total issued share capital of the Company was US\$514,584 divided into 514,584,000 Shares.

The capital structure of the Group was 89.1% debt and 10.9% equity as at 30 June 2024, compared with 62.6% debt and 37.4% equity as at 30 June 2023.

## Completion of issue of Convertible Bonds under specific mandate

On 20 February 2023, the Board announced that all the conditions precedent under the Subscription Agreement have been fulfilled and the Convertible Bonds in the aggregated principal amount of RMB300 million have been issued to the Investor. The Convertible Bonds are convertible into the Company's ordinary Shares of US\$0.001 each at an initial Conversion Price of HK\$4.81 per Conversion Share (subject to adjustments). The Conversion Shares has been issued by the Company pursuant to the specific mandate granted to the Directors at the extraordinary general meeting held on 11 January 2023 which authorised the Company to issue and allot up to 68,493,150 Shares to the Investor. The interest rate is 6% per annum on the outstanding principal amount of the Convertible Bonds.

The reasons for the issue of Convertible Bonds are as follows: the Company is in need of capital for its operation and R&D of pipeline and commercialisation of its products. The Company wants to seek an experienced and reputable business partner in the industry to assist its R&D and commercialisation of its products. As the Investor was one of the cornerstone investors of the Listing and is familiar with the business of the Company, the Directors consider the issue of the Convertible Bonds to raise funds will provide an opportunity for the Company to enhance its working capital and financial position and support the business development of the Group. They also consider that the issue of the Convertible Bonds is an appropriate means of raising additional capital for the Company since it will not have an immediate dilution effect on the shareholding of the existing Shareholders. The Company has considered alternative financing methods such as internal cash resources or bank financing that was available to the Company. Given that the Company is currently still in pre-revenue stage, most commercial banks in the PRC were only available to provide fundings under the condition that the Company has achieved positive cash flow. Taking into consideration the prevailing market condition, the financial position of the Group, and the Company's funding needs for its operation, R&D and commercialisation of its products, the Directors consider that it is a prudent way to issue the Convertible Bonds, even the Shareholders may suffer dilution effects under the Convertible Bonds upon conversion of the Conversion Shares (if any).

Details of the Convertible Bonds are set out in the circular of the Company dated 16 December 2022.

## Management Discussion and Analysis

In February 2023, the Company received the aggregate principal amount of RMB300.0 million, of which (a) approximately RMB102.3 million will be applied for EAL<sup>®</sup> clinical trial and the Company is expected to utilise the remaining fund by the first half of the year 2025; and (b) approximately RMB197.7 million will be applied for the construction costs of new R&D and production centres and the Company is expected to utilise the remaining fund by the end of 2025.

As at 30 June 2024, the Company utilised a total of approximately RMB192.7 million of the proceeds. The table below sets out the planned applications of the net proceeds from the Convertible Bonds and actual usage up to 30 June 2024:

Use of proceeds	Allocation of the net proceeds from the Convertible Bonds (RMB million)	Unutilised amount as at 1 January 2024 (RMB million)	Utilised amount up to 30 June 2024 (RMB million)	Utilised amount (from 1 January 2024 to 30 June 2024) (RMB million)	Unutilised amount as at 30 June 2024 (RMB million)	Expected timeline of full utilisation of the remaining net proceeds from the Convertible Bonds
EAL <sup>®</sup> clinical trial	102.3	43.2	91.7	32.6	10.6	By the first half of 2025 <sup>(1)</sup>
Construction costs of new research and development and production centres	197.7	117.7	101.0	21.0	96.7	By the end of 2025
<b>Total</b>	<b>300.0</b>	<b>160.9</b>	<b>192.7</b>	<b>53.6</b>	<b>107.3</b>	

(1) As at 30 June 2024, the delay in the actual use of proceeds for the EAL<sup>®</sup> clinical trial was mainly due to the delay in the approval process of EAL<sup>®</sup>.

### FOREIGN EXCHANGE

Foreign currency risk refers to the risk of loss resulting from changes in foreign currency exchange rates. Fluctuations in exchange rates between RMB and other currencies in which the Group conducts business may affect its financial condition and results of operation. The Group mainly operates in the PRC and is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to Hong Kong dollars. The conversion of foreign currencies into RMB, including Hong Kong dollars, has been based on rates set by the People's Bank of China. The Group seeks to limit its exposure to foreign currency risk by closely monitoring and minimising its net foreign currency position. During the Reporting Period, the Group did not enter into any currency hedging transactions.

# Management Discussion and Analysis

## SELECTED FINANCIAL RATIO

The following table sets out certain selected financial ratios as at the balance sheet dates indicated:

	As at 30 June 2024 (unaudited)	As at 31 December 2023 (audited) (restated)
Current ratio <sup>(1)</sup>	<b>0.38</b>	0.40
Quick ratio <sup>(2)</sup>	<b>0.36</b>	0.39
Gearing ratio <sup>(3)</sup>	–	–

Notes:

- (1) Current ratio equals current assets divided by current liabilities as at the end of the period.
- (2) Quick ratio equals (a) current assets less materials for research and development project divided by (b) current liabilities as at the end of the period.
- (3) Gearing ratio equals total borrowings divided by total equity as at the end of the period. As at 30 June 2024, the Group had no interest-bearing borrowings, such that the gearing ratio is not applicable for the six months ended 30 June 2024.

The current ratio decreased from 0.40 as at 31 December 2023 to 0.38 as at 30 June 2024 and the quick ratio decreased from 0.39 as at 31 December 2023 to 0.36 as at 30 June 2024. Such decreases were primarily due to financial assets at FVTPL of the Group decreased from approximately RMB124.8 million as at 31 December 2023 to approximately RMB65.7 million as at 30 June 2024.



## Other Information

### INTERIM DIVIDEND

No dividend was paid, declared or proposed during the Reporting Period.

### USE OF NET PROCEEDS FROM LISTING AND OVER-ALLOTMENT OPTION

The Shares were listed on the Main Board of the Stock Exchange on 10 July 2020. Subsequently, the Company announced that the over-allotment option described in the Prospectus was partially exercised by the joint representatives, on behalf of the international underwriters, on 31 July 2020, in respect of an aggregate of 14,584,000 Shares representing approximately 14.58% of the total number of the Shares initially available under the Global Offering before any exercise of the over-allotment option to facilitate the return to Tan Zheng Ltd of the borrowed Shares under the stock borrowing agreement which were used to cover over-allocations in the international offering.

After deducting the underwriting fees and commissions, other listing expenses and other estimated expenses in connection with the exercise of the initial Global Offering and the exercise of the over-allotment option, the net proceeds amounted to approximately HK\$1,127.8 million. As at 30 June 2024, the Company used a total of approximately HK\$1,124.8 million of the proceeds, including approximately HK\$385.6 million for investment in the ongoing clinical trial and commercialisation of EAL<sup>®</sup>, approximately HK\$374.5 million for investments in CAR-T-19 clinical trial and TCR-T product series candidates, approximately HK\$212.5 million for R&D expenditure in connection with expansion of other clinical indications for EAL<sup>®</sup>, approximately HK\$95.8 million for development of other product candidates in the product pipeline including R&D expenditure and the construction costs of new R&D and production centres and approximately HK\$56.4 million for working capital and other general corporate purposes. The Company intends to apply such net proceeds in accordance with the purposes as set out in the Prospectus.

## Other Information

The table below sets out the planned applications of the net proceeds from the Global Offering and the over-allotment option and actual usage up to 30 June 2024:

Use of Proceeds	Allocation of the net proceeds from the Global Offering (HK\$ million)	Percentage of total net proceeds (%)	Unutilised amount (as at 1 January 2024) (HK\$ million)	Utilised amount (from the Listing Date to 30 June 2024) (HK\$ million)	Utilised amount (from 1 January 2024 to 30 June 2024) (HK\$ million)	Unutilised amount (as at 30 June 2024) (HK\$ million)	Expected timeline of full utilisation of the remaining proceeds from the Global Offering as at 30 June 2024 <sup>(1)</sup>
For investment in the ongoing clinical trial and commercialization of EAL®	385.6	34.2	-	385.6	-	-	N/A
For R&D expenditure in connection with expansion of other clinical indications for EAL®	213.2	18.9	0.7	212.5	-	0.7	By the end of 2025
For investments in CAR-T-19 clinical trial and TCR-T product series candidates	374.5	33.2	-	374.5	-	-	N/A
Development of other product candidates in the product pipeline including R&D expenditure and the construction costs of new R&D and production centres	98.1	8.7	2.3	95.8	-	2.3	By the end of 2025
Working capital and other general corporate purposes	56.4	5.0	-	56.4	-	-	N/A
<b>Total</b>	<b>1,127.8</b>	<b>100.0</b>	<b>3.0</b>	<b>1,124.8</b>	<b>-</b>	<b>3.0</b>	

Note:

(1) The expected timeline of full utilisation is based on the Directors' best estimation barring unforeseen circumstances.

The net proceeds were used according to the planned usage previously disclosed. For the Company's planned usage of the net proceeds as described above, the Company expects the net proceeds will be used up by the end of 2025.

### SIGNIFICANT INVESTMENTS, MATERIAL ACQUISITIONS AND DISPOSALS

As at 30 June 2024, the Group recorded financial assets at FVTPL amounting to approximately RMB65.7 million, which included unlisted limited partner interests, financial products and certificates of deposits.

On 20 March 2023 and 20 June 2023, the Group (through its indirect wholly-owned subsidiary, Beijing Yongtai) subscribed for certain certificates of deposits issued by Minsheng Bank with its idle own funds in the principal amount of RMB110.0 million in aggregate. On 20 July 2023, 20 March 2024 and 20 June 2024, the Group disposed of eight out of the 11 certificates of deposits in three instalments by on-market sale through Minsheng Bank at an aggregate consideration of approximately RMB82.6 million. As at the date of this interim report, the Group continues to hold three certificates of deposits in the total amount of RMB30.0 million. For further details, please refer to the announcement of the Company dated 20 June 2024.

None of the investment that was designated as financial assets at FVTPL in the Group's investment portfolio had a carrying amount that accounts for 5% or more of the Group's total assets as at 30 June 2024.

Save as disclosed and as at the date of this interim report, there were no significant investments held by the Group or future plans regarding significant investment or capital assets.

## Other Information

### EMPLOYEE AND REMUNERATION POLICY

As at 30 June 2024, the Group had a total of 201 employees in the PRC and one employee in Korea. The total amount of employee remuneration of the Group (including Directors' remuneration) for the six months end 30 June 2024 was approximately RMB36.6 million (the six months ended 30 June 2023: approximately RMB38.3 million).

The following table sets forth the number of employees of the Group for each function as at 30 June 2024:

Function	Number of Employees
General management and administration	29
Research and development	22
Senior management	10
Product and technology R&D	30
Production, purification, equipment and safety	37
Quality	45
Clinical support and business development	29
<b>Total</b>	<b>202</b>

The Group has designed an evaluation system to assess the performance of its employees periodically. Such system forms the basis of its determinations of whether an employee should receive a salary raise, bonus, or promotion. The Group believed the salaries and bonuses the employees receive are competitive with market rates.

The Group places strong emphasis on providing training to its employees in order to enhance their technical and product knowledge. The Group designs and offers different training programmes for its employees in various positions.

The Group makes contributions to the social insurance and housing provident fund for all its employees in the PRC.

### FUNDING AND TREASURY POLICY

The Group adopts a stable, conservative approach in its finance and treasury policy, aiming to maintain an optimal financial position, the most economic finance costs, and minimal financial risks. Cash and cash equivalents are normally placed at financial institutions that the Group considers the credit risk to be low. The Group regularly reviews its funding requirements to maintain adequate financial resources in order to support its business operations as well as its R&D, future investments and expansion plans.

## Other Information

### DIRECTORS' AND CHIEF EXECUTIVE INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

As at the date of this interim report, the interests and short positions of the Directors of and chief executives of the Company in the ordinary Shares, underlying Shares and debentures of the Company or any of its associated corporations (as defined in Part XV of the SFO which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have under such provisions of the SFO), or were required, pursuant to section 352 of the SFO, to be entered in the register referred to therein, or were required to be notified to the Company and the Stock Exchange pursuant to the Model Code, are set out as follows:

#### (i) Interest in Shares and underlying Shares

Name	Capacity/Nature of Interest	Number of Shares held <sup>(1)</sup>	Approximate percentage of shareholding in the Company
<b>Directors</b>			
Mr. Tan Zheng <sup>(2)</sup>	Beneficial interest	5,000,000 (L)	0.97%
	Interest in controlled corporation	180,480,000 (L)	35.07%
Dr. Wang Yu <sup>(3)</sup>	Beneficial interest	23,450,000 (L)	4.56%
<b>Chief Strategy Officer</b>			
Mr. Jung Hyun Chul <sup>(4)</sup>	Interest in controlled corporation	44,820,000 (L)	8.71%

Notes:

- (1) The letter L denotes "long position" (as defined under Part XV of the SFO) of the relevant person/entity in such Shares.
- (2) Mr. Tan Zheng was interested as a grantee of share options subscribe for up to 5,000,000 Shares under the Pre-IPO Share Option Scheme (as defined below).  
  
Pursuant to the Proxy Agreement (as defined below), the passive minority shareholders have irrevocably entrusted their voting rights at any general meeting of the Company to Tan Zheng Ltd, such that it may exercise such voting rights with absolute discretion and hence it is deemed to be interested in the Shares held by the passive minority shareholder. Among the 180,480,000 Shares held by Tan Zheng Ltd, 142,080,000 Shares were entrusted by the passive minority shareholders pursuant to the Proxy Agreement (as defined below). Tan Zheng Ltd is a company wholly-owned by Mr. Tan Zheng. Accordingly, Mr. Tan Zheng is deemed to be interested in the 180,480,000 Shares held/deemed to be interested in by Tan Zheng Ltd.
- (3) Dr. Wang Yu was interested as a grantee of share options subscribe for up to 23,450,000 Shares under the Pre-IPO Share Option Scheme (as defined below).
- (4) These Shares are held by Evodevo Ltd, a company wholly-owned by Mr. Jung Hyun Chul. Accordingly, Mr. Jung Hyun Chul is deemed to be interested in the Shares held by Evodevo Ltd.

## Other Information

### (ii) Interest in associated corporations

Name of Director	Nature of Interest	Name of other member of the Group	Registered capital	Percentage of interest in the associated corporation
Mr. Tan Zheng	Beneficial interest	Yongtai Ruike	RMB30,000,000	60.00%
Dr. Wang Yu	Beneficial interest	Yongtai Ruike	RMB20,000,000	40.00%

Save as disclosed above, as at the date of this interim report, none of the Directors or chief executives of the Company had any interests or short positions in the Shares or underlying Shares or debentures of the Company or any of its associated corporations (as defined in Part XV of the SFO) which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have under such provisions of the SFO), or were required, pursuant to Section 352 of the SFO, to be entered in the register referred to therein, or were required to be notified to the Company and the Stock Exchange pursuant to the Model Code.

### **SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES**

As at the date of this interim report, to the best knowledge of the Directors, the following persons (other than the Director or chief executive of the Company) had an interest or a short positions in the Shares or underlying Shares of the Company which were required to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO and recorded in the register of the Company maintained under Section 336 of the SFO:

## Other Information

Name of Shareholder	Nature of Interest	Number of Shares held <sup>(1)</sup>	Approximate percentage of shareholding
China Resources Company Limited <sup>(2)(3)</sup>	Interested in controlled corporation	217,054,121 (L)	42.18%
China Resources Pharmaceutical Group Limited <sup>(2)(3)</sup>	Interested in controlled corporation	217,054,121 (L)	42.18%
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. <sup>*(2)(3)</sup> (華潤三九醫藥股份有限公司)	Interested in controlled corporation	165,595,721 (L)	32.18%
Beijing Pharmaceutical Investment and Management (BVI) Limited <sup>(2)</sup>	Beneficial interest	51,458,400 (L)	10.00%
Tasly Holding Group Co., Ltd. <sup>*(3)</sup> (天士力控股集團有限公司)	Interested in controlled corporation Person having a security interest in shares	165,595,721 (L) 26,000,000 (L)	32.18% 5.05%
Tasly Pharmaceutical Group Co., Ltd. <sup>*(3)</sup> (天士力醫藥集團股份有限公司)	Interested in controlled corporation Person having a security interest in shares	165,595,721 (L) 26,000,000 (L)	32.18% 5.05%
Tianjin Zhongzhi Technology Development Co., Ltd. <sup>*(3)</sup> (天津眾智科技發展有限公司)	Interested in controlled corporation Person having a security interest in shares	165,595,721 (L) 26,000,000 (L)	32.18% 5.05%
Tasly (Hong Kong) Pharmaceutical Investment Limited <sup>(3)</sup>	Beneficial interest Person having a security interest in shares	165,595,721 (L) 26,000,000 (L)	32.18% 5.05%
Li Yunhui	Interested in controlled corporation Person having a security interest in shares	165,595,721 (L) 26,000,000 (L)	32.18% 5.05%
Wu Naifeng	Interested in controlled corporation Person having a security interest in shares	165,595,721 (L) 26,000,000 (L)	32.18% 5.05%
Yan Kaijing	Interested in controlled corporation Person having a security interest in shares	165,595,721 (L) 26,000,000 (L)	32.18% 5.05%

\* English name are for identification purpose only.



## Other Information

Name of Shareholder	Nature of Interest	Number of Shares held <sup>(1)</sup>	Approximate percentage of shareholding
Yan Xijun	Interested in controlled corporation	165,595,721 (L)	32.18%
	Person having a security interest in shares	26,000,000 (L)	5.05%
Tan Zheng Ltd <sup>(4)</sup>	Beneficial interest	38,400,000 (L)	7.46%
	Interest of a party to an agreement	142,080,000 (L)	27.61%
Evodevo Ltd	Beneficial interest	44,820,000 (L)	8.71%
Greater Bay Area Homeland Development Fund (GP) Limited <sup>(5)</sup>	Interested in controlled corporation	32,998,619 (L)	6.41%
Greater Bay Area Homeland Development Fund LP <sup>(5)</sup>	Interested in controlled corporation	32,998,619 (L)	6.41%
Poly Platinum <sup>(5)</sup>	Beneficial interest	32,998,619 (L)	6.41%
Tan Xiaoyang <sup>(6)</sup>	Interest of controlled corporation/Interest of spouse	59,794,286 (L)	11.62%
Tan Xiao Yang Ltd <sup>(6)</sup>	Other	46,080,000 (L)	8.95%
Tan Yueyue <sup>(6)</sup>	Interested in controlled corporation/Interest of spouse	59,794,286 (L)	11.62%
Zhang Junzheng <sup>(7)</sup>	Other/Interest of spouse	43,680,714 (L)	8.49%
Zhang Jun Zheng Ltd <sup>(7)</sup>	Other	41,691,428 (L)	8.10%
Wang Minhui <sup>(7)</sup>	Interested in controlled corporation/Interest of spouse	43,680,714 (L)	8.49%

## Other Information

### Notes:

- (1) The letter L denotes “long position” (as defined under Part XV of the SFO) of the relevant person/entity in such Shares. As at the date of this interim report, the issue Shares comprised 514,584,000 Shares.
- (2) These 217,054,121 Shares comprise 51,458,400 Shares held by Beijing Pharmaceutical Investment and Management (BVI) Limited and 165,595,721 Shares held by Tasly (Hong Kong) Pharmaceutical Investment Limited. On 4 August 2024, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. entered into a share purchase agreement dated 4 August 2024 with Tasly Biopharmaceuticals Industry Group Co., Ltd., Tianjin Heyue Technology Development Partnership Enterprise (Limited Partnership), Tianjin Kangshun Technology Development Partnership Enterprise (Limited Partnership), Tianjin Shunqi Technology Development Partnership Enterprise (Limited Partnership), Tianjin Shanzhen Technology Development Partnership Enterprise (Limited Partnership), Tianjin Tongming Technology Development Partnership Enterprise (Limited Partnership) and Tianjin Hongxun Technology Development Partnership Enterprise (Limited Partnership) (collectively, the “**Vendors**” and each a “**Vendor**”), pursuant to which China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. had agreed to conditionally purchase, and the Vendors had agreed to conditionally sell, an aggregate of 418,306,002 shares of Tasly Pharmaceuticals Group Co., Ltd.. For details, please refer to the announcement of China Resources Pharmaceutical Group Limited dated 4 August 2024. Tasly (Hong Kong) Pharmaceutical Investment Limited is an indirect wholly owned subsidiary of Tasly Pharmaceutical Group Co., Ltd.\* (天士力醫藥集團股份有限公司), which in turn would be owned as to 28.0% by China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. upon completion of the share purchase agreement as abovementioned. China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is in turn owned as to 63.02% by China Resources Pharmaceutical Holdings Limited\* (華潤醫藥控股有限公司), a company wholly-owned by China Resources Pharmaceutical Group Limited. Beijing Pharmaceutical Investment and Management (BVI) Limited is a company wholly-owned by China Resources Pharmaceutical Group Limited which is indirectly owned as to 53.39% by China Resources Company Limited. China Resources Pharmaceutical Group Limited and China Resources Company Limited are deemed to be interested in the Shares held by Beijing Pharmaceutical Investment and Management (BVI) Limited.
- (3) These 165,595,721 Shares comprise 97,102,571 Shares held by Tasly (Hong Kong) Pharmaceutical Investment Limited and 68,493,150 Shares are unlisted derivatives – convertible instruments. As at the date of this interim report, the Convertible Bonds has not been converted. Assuming upon full conversion of the Convertible Bonds at the initial conversion price of HK\$4.81 per conversion share (assuming that there is no other change in the issued share capital of the Company), the approximate shareholding of the Company held by Tasly (Hong Kong) Pharmaceutical Investment Limited is 12.94%. For details, please refer to the announcement of the Company dated 30 October 2022.
- (4) Pursuant to a proxy agreement dated 29 August 2019 (the “**Proxy Agreement**”), the passive minority shareholders have irrevocably entrusted their voting rights at any general meeting of the Company to Tan Zheng Ltd, such that it may exercise such voting rights with absolute discretion and hence it is deemed to be interested in the Shares held by the passive minority shareholders.  
  
Among the Shares, 19,285,714 Shares was pledged to the Investor pursuant to the Subscription Agreement.
- (5) Poly Platinum is a wholly-controlled subsidiary of Greater Bay Area Homeland Development Fund LP (大灣區共同家園發展基金有限合夥) (“**Greater Bay Area Fund**”). According to Poly Platinum, the general partner of Greater Bay Area Fund is Greater Bay Area Homeland Development Fund (GP) Limited. Accordingly, each of Greater Bay Area Homeland Development Fund (GP) Limited and Greater Bay Area Fund is deemed to be interested in the Shares held by Poly Platinum.
- (6) These 59,794,286 Shares comprises 46,080,000 Shares held by Tan Xiao Yang Ltd and 13,714,286 Shares held by a company controlled by Ms. Tan Yueyue. Tan Xiao Yang Ltd is a company wholly-owned by Mr. Tan Xiaoyang, who is deemed to be interested in Shares held by Tan Xiao Yang Ltd. Ms. Tan Yueyue is the spouse of Mr. Tan Xiaoyang and Tan Yue Yue Ltd is a company wholly-owned by Ms. Tan Yueyue. Among the Shares, 6,714,286 Shares held by Tan Yue Yue Ltd was pledged to the Investor pursuant to the Subscription Agreement.  
  
Mr. Tan Xiao Yang and Tan Xiao Yang Ltd are the passive minority shareholders which entrusted their voting rights in the Company in Tan Zheng Ltd pursuant to the Proxy Agreement.
- (7) These 43,680,714 Shares comprises 41,691,428 Shares held by Zhang Jun Zheng Ltd and 1,989,286 Shares held by a company controlled by Ms. Wang Minhui. Zhang Jun Zheng Ltd is a company wholly-owned by Mr. Zhang Junzheng, who is deemed to be interested in the Shares held by Zhang Jun Zheng Ltd. Ms. Wang Minhui is the spouse of Mr. Zhang Junzheng.  
  
Mr. Zhang Junzheng and Zhang Jun Zheng Ltd are the passive minority shareholders which entrusted their voting rights in the Company in Tan Zheng Ltd pursuant to the Proxy Agreement.

Save as disclosed above, as at the date of this interim report, the Directors have not been aware of any person (other than the Directors or chief executives of the Company) who had interests or short positions in the Shares or underlying Shares of the Company which would be required to be disclosed under the provisions of Divisions 2 and 3 of Part XV of the SFO or to be recorded in the register maintained under Section 336 of the SFO.

## Other Information

### SHARE OPTION SCHEMES

In order to reward the participants defined thereunder for their contribution to the Group's success and to provide them with incentives to further contribute to the Group, the Company adopted the pre-IPO share option scheme (the "**Pre-IPO Share Option Scheme**") on 31 December 2019 and the post-IPO share option scheme (the "**Post-IPO Share Option Scheme**") on 6 June 2020.

For details of the principal terms of the Pre-IPO Share Option Scheme and the Post-IPO Share Option Scheme, please refer to Appendix IV to the Prospectus.

#### Pre-IPO Share Option Scheme

The summary of the share options granted under the Pre-IPO Share Option Scheme that were still outstanding as at 30 June 2024 is as follows:

Name of the grantees	No. of share options outstanding as at 31 December 2023	No. of share options granted during the Reporting Period and up to 30 June 2024	No. of share options exercised during the Reporting Period and up to 30 June 2024	No. of share options cancelled during the Reporting Period and up to 30 June 2024	No. of share options lapsed during the Reporting Period and up to 30 June 2024	No. of share options outstanding as at 30 June 2024
Tan Zheng <i>Chairman and executive Director</i>	5,000,000	-	-	-	-	5,000,000
Wang Yu <i>Executive Director, CEO and CTO</i>	23,450,000	-	-	-	-	23,450,000
Employees (in aggregate)	7,480,000	-	-	-	-	7,480,000
<b>Total</b>	<b>35,930,000</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>35,930,000</b>

## Other Information

Details regarding the number of share options, date of grant, vesting period, exercise period and exercise price of the share options granted under the Pre-IPO Share Option Scheme that were still outstanding as at 30 June 2024 are set out below:

Name of the grantees	Date of grant	Vesting Period	Exercise Period	Exercise Price per share <sup>(2)</sup>	No. of outstanding share option as at 30 June 2024
Tan Zheng <i>Chairman and executive Director</i>	31 December 2019	Two equal tranches on 31 December 2020 and 2021, respectively	31 December 2019 to 30 December 2026	HK\$5.5	5,000,000
Wang Yu <i>Executive Director, CEO and CTO</i>	31 December 2019	Two equal tranches on 31 December 2020 and 2021, respectively	31 December 2019 to 30 December 2026	HK\$5.5	23,450,000
Employees (in aggregate)	31 December 2019	Three tranches of 30%, 30% and 40% on 31 December 2020, 2021 and 2022, respectively/ Two equal tranches on 31 December 2020 and 2021, respectively <sup>(1)</sup>	31 December 2019 to 30 December 2026	HK\$5.5	7,480,000
<b>Total</b>					<b>35,930,000</b>

Notes:

- (1) For details of the vesting periods of share options granted to each of the employees, please refer to Appendix IV to the Prospectus.
- (2) Closing price of the Shares is not applicable as the Shares were not listed at the date of grant.

As at the date of this interim report, the total number of Shares available for issue under the Pre-IPO Share Option Scheme is 35,930,000 Shares, representing approximately 6.98% of the total issued Shares.

### Post-IPO Share Option Scheme

The Post-IPO Share Option Scheme will remain in force for a maximum period of 10 years commencing on the date on which the Post-IPO Share Option Scheme is adopted.

At the beginning and the end of the Reporting Period, the number of share options available for grant under the Post-IPO Share Option Scheme were 12,500,000 and 12,500,000, respectively.

No share options were granted, exercised, cancelled or lapsed under the Post-IPO Option Scheme during the period from the Listing Date to the date of this interim report.

## Other Information

### **COMPLIANCE WITH CORPORATE GOVERNANCE CODE**

The Group is committed to maintaining high standard of corporate governance to safeguard the interests of the Shareholders, enhance corporate value, formulate its business strategies and policies, and enhance its transparency and accountability.

The Company's corporate governance practices are based on the principles and code provisions as set out in the CG Code contained in Appendix C1 to the Listing Rules and the Company has adopted the CG Code as its own code of corporate governance. The Board is of the view that the Company has complied with all applicable code provisions of the CG Code throughout the six months ended 30 June 2024. The Board will periodically review and enhance its corporate governance practices to ensure that the Company continues to meet the requirements of the CG Code.

### **COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS**

The Company has adopted the Model Code as set out in Appendix C3 to the Listing Rules to regulate all dealings by Directors and relevant employees in securities of the Company and other matters covered by the Model Code.

Specific enquiry has been made to each Director and all Directors have confirmed that they have complied with the applicable standards set out in the Model Code during the six months ended 30 June 2024. No incident of non-compliance of the Model Code by the relevant employees was noted by the Company.

### **DIRECTORS' INTEREST IN CONTRACTS**

None of the Directors had a material interest, either directly or indirectly, in any contract of significance to the business of the Group to which the Company, or any of its subsidiaries or fellow subsidiaries was a party throughout the Reporting Period and up to the date of this interim report.

### **PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES**

As at 30 June 2024, there is no treasury shares held by the Company.

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the shares (including sale of treasury shares) for the six months ended 30 June 2024.

## Other Information

### **AUDIT COMMITTEE AND REVIEW OF FINANCIAL REPORT**

The Audit Committee was established on 6 June 2020 with written terms of reference in compliance with Rule 3.21 of the Listing Rules and the CG Code as set out in Appendix C1 to the Listing Rules. As at the date of this interim report, the Audit Committee consists of three members, being two independent non-executive Directors, namely Mr. NG Chi Kit, who is the chairman of the Audit Committee, Professor WANG Yingdian, and one non-executive Director, namely Mr. TAO Ran. Mr. Ng Chi Kit is an independent non-executive Director possessing the appropriate professional qualifications or accounting or related financial management expertise as required under Rule 3.10(2) of the Listing Rules.

The primary duties of the Audit Committee are to provide the Directors with an independent review of the effectiveness of the financial reporting process, internal control and risk management system of the Group, to oversee the audit process and to perform other duties and responsibilities as assigned by the Directors.

The Audit Committee has reviewed the Company's unaudited consolidated interim results for the six months ended 30 June 2024, and confirms that the applicable accounting principles, standards and requirements have been complied with, and that adequate disclosures have been made. The interim results for the six months ended 30 June 2024 are unaudited, but have been reviewed by the auditor, in accordance with Hong Kong Standard on Review Engagements 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Hong Kong Institute of Certified Public Accountants.

### **CHANGES TO DIRECTORS' INFORMATION**

There has been no change in the Directors' biographical details which are required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules since publication of the Group's 2023 Annual Report up to 23 August 2024 (being the date of approval of this interim report).

### **DIRECTORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES**

Save for the Pre-IPO Share Option Scheme and the Post-IPO Share Option Scheme, no arrangement has been made by the Company or any of its subsidiaries for any Director to acquire benefits by means of the acquisition of Shares in or debentures of the Company or any other body corporate, and no rights to any share capital or debt securities of the Company or any other body corporate were granted to any Director or their respective spouse or children under 18 years of age, nor were any such rights exercised during or at the end of the Reporting Period.



## Other Information

### **PUBLICATION OF THE INTERIM RESULTS AND 2024 INTERIM REPORT ON THE WEBSITES OF THE STOCK EXCHANGE AND THE COMPANY**

The interim results announcement is published on the websites of the Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)) and the Company ([www.eaal.net](http://www.eaal.net)), and this interim report of the Group for the six months ended 30 June 2024 is now available on the respective websites of the Stock Exchange and the Company. The Company has set out in detail on its website under the “Investor Relations” section the manner for the dissemination of its corporate communications, and the relevant arrangements for Shareholders to request for corporate communications in printed form. Shareholders may send a written request to the Company’s Hong Kong branch Share registrar, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong or send an email to [immunotech.ecom@computershare.com.hk](mailto:immunotech.ecom@computershare.com.hk), requesting for a printed copy of this interim report.

Shareholders are encouraged to access the corporate communications of the Company through the websites of the Stock Exchange and the Company in lieu of receiving printed copies to help protect the environment.

### **EVENTS AFTER THE REPORTING PERIOD**

Save as disclosed, so far as the Company is aware, there was no important event affecting the Group which occurred after the end of the Reporting Period up to the date of this interim report.

# Report on Review of Condensed Consolidated Financial Statements

## TO THE BOARD OF DIRECTORS OF IMMUNOTECH BIOPHARM LTD

*(incorporated in the Cayman Islands with limited liability)*

### INTRODUCTION

We have reviewed the condensed consolidated financial statements of Immunotech Biopharm Ltd (the “**Company**”) and its subsidiaries (collectively referred to as the “**Group**”) set out on pages 35 to 57, which comprise the condensed consolidated statement of financial position as of 30 June 2024 and the related condensed consolidated statement of profit or loss and other comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the six-month period then ended, and notes to the condensed consolidated financial statements. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 “Interim Financial Reporting” (“**IAS 34**”) issued by the International Accounting Standards Board. The directors of the Company are responsible for the preparation and presentation of these condensed consolidated financial statements in accordance with IAS 34. Our responsibility is to express a conclusion on these condensed consolidated financial statements based on our review, and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

### SCOPE OF REVIEW

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” (“**HKSRE 2410**”) issued by the Hong Kong Institute of Certified Public Accountants. A review of these condensed consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34.

# Report on Review of Condensed Consolidated Financial Statements

## **OTHER MATTER**

The comparative condensed consolidated statement of profit or loss and other comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the six-month period ended 30 June 2023 and the relevant notes to the condensed consolidated financial statements have not been reviewed in accordance with HKSRE 2410.

### **Deloitte Touche Tohmatsu**

*Certified Public Accountants*

Hong Kong

23 August 2024

# Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

For the six months ended 30 June 2024

	NOTES	For the six months ended 30 June	
		2024 RMB'000 (unaudited)	2023 RMB'000 (unaudited)
Other income	5	<b>6,526</b>	5,533
Other gains and losses, net	6	<b>19,836</b>	(20,269)
Administrative expenses		<b>(23,048)</b>	(25,035)
Research and development expenses		<b>(91,118)</b>	(74,315)
Finance costs		<b>(3,851)</b>	(4,372)
Other expenses		<b>(901)</b>	(144)
Loss before tax		<b>(92,556)</b>	(118,602)
Income tax expense	7	<b>–</b>	–
Loss and total comprehensive expense for the period	8	<b>(92,556)</b>	(118,602)
Loss and total comprehensive expense for the period attributable to:			
Owners of the Company		<b>(92,515)</b>	(118,114)
Non-controlling interests		<b>(41)</b>	(488)
		<b>(92,556)</b>	(118,602)
Loss per share (RMB)	10		
– Basic		<b>(0.18)</b>	(0.23)
– Diluted		<b>(0.18)</b>	(0.23)

# Condensed Consolidated Statement of Financial Position

At 30 June 2024

	NOTES	As at 30 June 2024 RMB'000 (unaudited)	As at 31 December 2023 RMB'000 (audited) (restated)
<b>NON-CURRENT ASSETS</b>			
Property, plant and equipment		<b>474,253</b>	500,759
Intangible assets		<b>21,410</b>	41,882
Prepayments, deposits and other receivables	11	<b>42,077</b>	42,113
Contract costs		<b>339</b>	464
Financial assets at fair value through profit or loss ("FVTPL")	12	<b>-</b>	46,362
Pledged bank deposits		<b>810</b>	810
		<b>538,889</b>	632,390
<b>CURRENT ASSETS</b>			
Contract costs		<b>253</b>	256
Financial assets at FVTPL	12	<b>65,665</b>	124,812
Materials for research and development project		<b>6,851</b>	4,924
Pledged bank deposits		<b>3,520</b>	1,023
Prepayments, deposits and other receivables	11	<b>24,896</b>	30,718
Bank balances and cash		<b>79,645</b>	52,161
		<b>180,830</b>	213,894
<b>CURRENT LIABILITIES</b>			
Contract liabilities		<b>3,029</b>	710
Trade and other payables	13	<b>162,388</b>	176,911
Lease liabilities		<b>26,288</b>	24,679
Deferred government grants	14	<b>710</b>	1,136
Other financial liabilities	15	<b>285,791</b>	326,839
		<b>478,206</b>	530,275
<b>NET CURRENT LIABILITIES</b>		<b>(297,376)</b>	(316,381)
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<b>241,513</b>	316,009

# Condensed Consolidated Statement of Financial Position

At 30 June 2024

	NOTE	As at 30 June 2024 RMB'000 (unaudited)	As at 31 December 2023 RMB'000 (audited) (restated)
<b>NON-CURRENT LIABILITIES</b>			
Contract liabilities		<b>1,159</b>	1,274
Lease liabilities		<b>97,220</b>	105,655
Deferred government grants	14	<b>64,800</b>	38,190
		<b>163,179</b>	145,119
<b>NET ASSETS</b>			
		<b>78,334</b>	170,890
<b>CAPITAL AND RESERVES</b>			
Share capital		<b>3,576</b>	3,576
Reserves		<b>77,525</b>	170,040
Equity attributable to owners of the Company		<b>81,101</b>	173,616
Non-controlling interests		<b>(2,767)</b>	(2,726)
<b>TOTAL EQUITY</b>			
		<b>78,334</b>	170,890

The condensed consolidated financial statements on pages 35 to 57 were approved and authorised for issue by the board of directors on 23 August 2024 and are signed on its behalf by:

**Tan Zheng**  
DIRECTOR

**Wang Yu**  
DIRECTOR

# Condensed Consolidated Statement of Changes in Equity

For the six months ended 30 June 2024

	Attributable to owners of the Company							Non-controlling interests	Total equity
	Share capital	Share premium	Capital reserve	Statutory surplus reserve	Share option reserve	Accumulated losses	Subtotal		
	RMB'000	RMB'000	RMB'000 (Note i)	RMB'000 (Note ii)	RMB'000 (Note 16)	RMB'000	RMB'000	RMB'000	RMB'000
<b>At 1 January 2023 (audited)</b>	3,576	1,402,498	180,349	2,001	205,339	(1,285,328)	508,435	(2,066)	506,369
Loss and total comprehensive expense for the period	-	-	-	-	-	(118,114)	(118,114)	(488)	(118,602)
<b>At 30 June 2023 (unaudited)</b>	3,576	1,402,498	180,349	2,001	205,339	(1,403,442)	390,321	(2,554)	387,767
<b>At 1 January 2024 (audited)</b>	<b>3,576</b>	<b>1,402,498</b>	<b>180,349</b>	<b>2,001</b>	<b>205,339</b>	<b>(1,620,147)</b>	<b>173,616</b>	<b>(2,726)</b>	<b>170,890</b>
Loss and total comprehensive expense for the period	-	-	-	-	-	(92,515)	(92,515)	(41)	(92,556)
<b>At 30 June 2024 (unaudited)</b>	<b>3,576</b>	<b>1,402,498</b>	<b>180,349</b>	<b>2,001</b>	<b>205,339</b>	<b>(1,712,662)</b>	<b>81,101</b>	<b>(2,767)</b>	<b>78,334</b>

Notes: i Capital reserve represents (i) the difference amounting to RMB191,990,000 of the capital contribution from certain investors of Immunotech Applied Science Limited\* (北京永泰生物制品有限公司) (“**Beijing Yongtai**”) and new paid-in capital issued to those investors; (ii) a net amount of RMB11,641,000 recognised against capital reserve arising from a group reorganization completed in 2018.

ii Pursuant to the relevant laws and regulations in the People’s Republic of China (the “**PRC**”), the PRC subsidiaries with limited liability are required to make annual appropriations to statutory surplus reserve of 10% of after-tax profits at each year end until the balance reaches 50% of the relevant PRC subsidiary’s registered capital.

\* English name are for identification purpose only.



# Condensed Consolidated Statement of Cash Flows

For the six months ended 30 June 2024

	For the six months ended 30 June	
	2024 RMB'000 (unaudited)	2023 RMB'000 (unaudited)
<b>NET CASH USED IN OPERATING ACTIVITIES</b>	<b>(79,516)</b>	(88,838)
<b>INVESTING ACTIVITIES</b>		
Payments for purchase of property, plant and equipment	<b>(19,650)</b>	(12,623)
Payments for intangible assets	<b>(151)</b>	(1,112)
Proceeds from disposal/redemption of financial assets at FVTPL	<b>108,832</b>	–
Purchases of financial assets at fair value through other comprehensive income (“FVTOCI”)	–	(110,000)
Proceeds from disposal of property, plant and equipment	<b>14</b>	820
Withdrawal of bank deposits with original maturity over three months	–	125,938
Placement of bank deposits with original maturity over three months	–	(125,000)
Government grants received	<b>30,740</b>	–
Interest received	<b>381</b>	502
Placement of pledged bank deposits	<b>(2,497)</b>	(856)
<b>NET CASH FROM (USED IN) INVESTING ACTIVITIES</b>	<b>117,669</b>	(122,331)
<b>FINANCING ACTIVITIES</b>		
Proceeds on issue of convertible bonds	–	300,000
Repayments of lease liabilities	<b>(6,826)</b>	(9,119)
Interest paid for lease liabilities	<b>(3,851)</b>	(4,353)
Interest paid on bank borrowings	–	(19)
<b>NET CASH (USED IN) FROM FINANCING ACTIVITIES</b>	<b>(10,677)</b>	286,509
<b>NET INCREASE IN CASH AND CASH EQUIVALENTS</b>	<b>27,476</b>	75,340
<b>CASH AND CASH EQUIVALENTS AT 1 JANUARY</b>	<b>52,161</b>	58,448
Effect of foreign exchange rate changes	<b>8</b>	(48)
<b>CASH AND CASH EQUIVALENTS AT 30 JUNE</b>	<b>79,645</b>	133,740

# Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2024

## 1. GENERAL INFORMATION

Immunotech Biopharm Ltd (the “**Company**”) was incorporated in the Cayman Islands as an exempted company with limited liability under the Companies Act Chapter 22 (Law of 3 of 1961, as consolidated and revised) of the Cayman Islands on 11 April 2018. Its ordinary shares have been listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) since 10 July 2020. The address of the Company’s registered office is at PO Box 309, Ugland House, Grand Cayman KY1-1104, Cayman Islands. The principal place of business of the Company is at 8/F, Block 1, Guosheng Technology Park, No.1 Kangding Street, Beijing Economic-Technological Development Area, Beijing, the PRC.

The principal activity of the Company is investment holding and its subsidiaries are mainly engaged in research and development, manufacturing and commercialisation of immune cell products for treatments of cancers in the PRC. The Company and its subsidiaries are hereinafter collectively referred to as the “**Group**”.

The condensed consolidated financial statements are presented in Renminbi (“**RMB**”), which is also the functional currency of the Group.

## 2. BASIS OF PREPARATION

The condensed consolidated financial statements of the Group have been prepared in accordance with International Accounting Standard 34 “**Interim Financial Reporting**” issued by the International Accounting Standards Board (the “**IASB**”) as well as the applicable disclosure requirements of the Rules Governing the Listing of Securities on the Stock Exchange.

In preparation of the condensed consolidated financial statements of the Group for the six months ended 30 June 2024, the directors of the Company (the “**Directors**”) have given careful consideration to the future liquidity of the Group in light of the fact that the Group’s accumulated losses has increased to RMB1,712,662,000 as at 30 June 2024 after recognising loss and total comprehensive expense attributable to owners of the Company RMB92,515,000 for the six months ended 30 June 2024, a net cash outflow of RMB79,516,000 used in operating activities for the six months ended 30 June 2024, and the Group will largely remain in research and development stage for the twelve-month period ending 30 June 2025.

The Directors have reviewed the Group’s cash flow projections prepared by management, which cover a period of not less than twelve months from 30 June 2024. The following plans and measures are formulated with the objective to improve the liquidity of the Group:

- i) The Group has obtained financial support committed by the ultimate parent company of a major shareholder of the Company (the “**Financial Supporting Party**”) who has agreed to provide necessary financial support to the Group not less than 15 months from 31 December 2023 including but not limited to utilizing existing available bank facilities of the Financial Supporting Party. Subsequent to 31 December 2023, the Group, the Financial Supporting Party and the bank have signed a memorandum of understanding that the bank will proceed with the bank lending procedures to the Group upon demand. The Directors have evaluated and are satisfied with the Financial Supporting Party’s capability of providing necessary financial support to the Group and such support is constantly applicable for the period of 14 months from 30 June 2024 to 31 August 2025,
- ii) The Group has initiated the redemption process in an investment at approximately RMB31 million, and

# Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2024

## 2. BASIS OF PREPARATION - CONTINUED

iii) The Group is actively in applying applicable government subsidies.

After due and careful evaluation, the Directors believe that the Group will be able to meet in full its financial obligations as and when they fall due in the next twelve months from the end of the reporting period. Accordingly, the condensed consolidated financial statements have been prepared on a going concern basis.

## 3. PRINCIPAL ACCOUNTING POLICIES

The condensed consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments, which are measured at fair values at the end of the reporting period.

Other than change in accounting policies resulting from application of amendments to International Financial Reporting Standards (“**IFRSs**”), and application of certain accounting policies which became relevant to the Group in the current interim period, the accounting policies and methods of computation used in the condensed consolidated financial statements for the six months ended 30 June 2024 are the same as those presented in the Group’s annual consolidated financial statements for the year ended 31 December 2023.

### Application of amendments to IFRSs

In the current interim period, the Group has applied the following amendments to IFRSs issued by the IASB, for the first time, which are mandatorily effective for the Group’s annual period beginning on 1 January 2024 for the preparation of the Group’s condensed consolidated financial statements:

Amendments to IFRS 16	Lease Liability in a Sale and Leaseback
Amendments to IAS 1	Classification of Liabilities as Current or Non-current
Amendments to IAS 1	Non-current Liabilities with Covenants
Amendments to IAS 7 and IFRS 7	Supplier Finance Arrangements

Except as described below, the application of the amendments to IFRSs in the current interim period has had no material impact on the Group’s financial positions and performance for the current and prior periods and/or on the disclosures set out in these condensed consolidated financial statements.

# Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2024

## 3. PRINCIPAL ACCOUNTING POLICIES - CONTINUED

### 3.1 Impacts on application of Amendments to IAS 1 Classification of Liabilities as Current or Non-current (the "2020 Amendments")

#### 3.1.1 Accounting policies

##### **Convertible bonds (with conversion options not meeting "fixed for fixed criterion")**

When determining the classification of convertible bonds as current or non-current, the Group considers both the redemption through cash settlement and the transfer of the Group's own equity instruments as a result of exercise of conversion options by holders as settlement of the convertible bonds.

#### 3.1.2 Transition and summary of impact

The Group has applied the new accounting policy and the amendments retrospectively. The application of the amendments in the current period has the following impacts on convertible bonds with conversion options not meeting "fixed for fixed criterion".

- (a) Convertible instruments with conversion options not meeting "fixed for fixed criterion" designated at FVTPL

The Group's outstanding convertible bonds include counterparty conversion options that do not meet equity instruments classification by applying IAS 32. The convertible bonds were designated at FVTPL. Upon the application of the 2020 Amendments, given that the convertible bonds are exercisable anytime as at, 31 December 2023, the convertible bonds designated at FVTPL as at 31 December 2023 are reclassified to current liabilities as the holders have the option to convert within twelve months after the reporting period.

Except as described above, the application of the 2020 Amendments has no other material impact on the classification of the Group's other liabilities. The change in accounting policy does not have impact to the Group's profit or loss or earnings per share for the six months ended 30 June 2023. The details of the impacts on each financial statement line item on the condensed consolidated statement of financial position arising from the application of the amendments are set out below in this Note. Comparative figures have been restated.

# Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2024

## 3. PRINCIPAL ACCOUNTING POLICIES - CONTINUED

### 3.1 Impacts on application of Amendments to IAS 1 Classification of Liabilities as Current or Non-current (the "2020 Amendments") - continued

#### 3.1.2 Transition and summary of impact - continued

- (a) Convertible instruments with conversion options not meeting "fixed for fixed criterion" designated at FVTPL - continued

The effects of the changes in accounting policy as a result of application of 2020 Amendments on the condensed consolidated statement of financial position as at the end of the reporting period 30 June 2024 and immediately preceding year 31 December 2023 are as follows:

	30 June 2024 (As reported) RMB'000	Adjustments RMB'000	30 June 2024 (Without the application of 2020 Amendments) RMB'000
<b>Current Liability</b>			
Other financial liabilities	–	285,791	285,791
<b>Non-current Liability</b>			
Other financial liabilities	285,791	(285,791)	–
<b>Total effects on net assets</b>	<b>285,791</b>	<b>–</b>	<b>285,791</b>

  

	31 December 2023 (Originally stated) RMB'000	Adjustments RMB'000	31 December 2023 (Restated) RMB'000
<b>Current Liability</b>			
Other financial liabilities	–	326,839	326,839
<b>Non-current Liability</b>			
Other financial liabilities	326,839	(326,839)	–
<b>Total effects on net assets</b>	<b>326,839</b>	<b>–</b>	<b>326,839</b>

# Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2024

## 4. SEGMENT INFORMATION

For the purposes of resources allocation and performance assessment, the executive directors of the Company, being the chief operating decision makers, review the consolidated results when making decisions about allocating resources and assessing performance of the Group as a whole and hence, the Group has only one operating and reportable segment and no further analysis of this single segment is presented.

### Geographical information

The Group did not record any revenue during the six months ended 30 June 2024 (the six months ended 30 June 2023: nil). As at 30 June 2024, the Group's non-current assets excluding financial instruments amounted to RMB534,360,000 (31 December 2023: RMB581,596,000). All of the Group's non-current assets are located in the PRC, accordingly, no analysis of geographical information is presented.

## 5. OTHER INCOME

	For the six months ended 30 June	
	2024 RMB'000 (unaudited)	2023 RMB'000 (unaudited)
Income from provision of cell cryopreservation services	355	355
Income from technical services	832	–
Interest income on bank balances and deposits	381	1,448
Interest income from lease deposits	97	96
Rental income from leasehold land	229	–
Interest income on financial assets at FVTOCI	–	848
Government grants		
– Research and development activities	428	2,617
– Machinery	4,128	66
– Others	76	103
<b>Total</b>	<b>6,526</b>	<b>5,533</b>

# Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2024

## 6. OTHER GAINS AND LOSSES, NET

	For the six months ended 30 June	
	2024 RMB'000 (unaudited)	2023 RMB'000 (unaudited)
Fair value gain (loss) on financial assets at FVTPL	<b>3,323</b>	(10,126)
Fair value gain (loss) on other financial liabilities	<b>41,048</b>	(10,152)
Termination loss of an intangible asset (Note)	<b>(19,316)</b>	–
Impairment loss on prepayment to a supplier (Note)	<b>(5,183)</b>	–
Exchange gain, net	<b>11</b>	76
Loss on disposal of property, plant and equipment	<b>(41)</b>	(83)
Others	<b>(6)</b>	16
<b>Total</b>	<b>19,836</b>	(20,269)

Note: On 11 January 2021, the Company entered into a license agreement with T-Cure Bioscience, Inc. (“**T-Cure**”), pursuant to which T-Cure agreed to grant an exclusive license to the Company to use the patent rights and technology of T-Cure for the development, manufacturing and commercialisation of licensed products in Korea, the PRC, including Hong Kong and Macau, but excluding Taiwan in the field of immunotherapy for renal cell carcinoma. As the transfer of the relevant technologies agreed upon in the agreement was completed in March 2022, the Company recorded an intangible asset in relation to the upfront payment and the first milestone payment with total amount of US\$3,000,000 (equivalent to RMB19,316,000) in 2022. During the current period, the license agreement was terminated and a loss of RMB19,316,000 was recognised for the related intangible asset since the Group did not plan to continue the development activities in relation to such licensed technology. In addition, the Group recognised an impairment loss for the prepayment to T-Cure of RMB5,183,000 in profit or loss.

# Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2024

## 7. INCOME TAX EXPENSE

	For the six months ended 30 June	
	2024	2023
	RMB'000	RMB'000
	(unaudited)	(unaudited)
Current PRC enterprise income tax ("EIT")	-	-

Under the law of the PRC on Enterprise Income Tax (the "EIT Law") and implementation regulations of the EIT Law, the basic tax rate of the Company's PRC subsidiaries is 25%.

Beijing Yongtai has been accredited as a "High and New Technology Enterprise" by the Science and Technology Bureau of Beijing and relevant authorities on 31 October 2018 for a term of three years, and has been registered with the local tax authorities for enjoying the reduced EIT rate of 15% and the unused tax losses could be utilised for 10 years since 2013. During the year ended 31 December 2021, the accreditation of "High and New Technology Enterprise" of Beijing Yongtai has been extended to December 2024. Beijing Yongtai Ruike Biotechnology Company Ltd\* (北京永泰瑞科生物科技有限公司) ("Yongtai Ruike") has been accredited as a "High and New Technology Enterprise" by the Science and Technology Bureau of Beijing and relevant authorities on 20 December 2023 for a term of three years, and has been registered with the local tax authorities for enjoying the reduced EIT rate of 15% and the unused tax losses could be utilised for 10 years since 2023. Accordingly, the profits derived by Beijing Yongtai is subject to EIT rate of 15% (the six months ended 30 June 2023: 15%) for the six months ended 30 June 2024, and the profits derived by Yongtai Ruike is subject to EIT rate of 15% (the six months ended 30 June 2023: 15%) for the six months ended 30 June 2024.

No provision for PRC EIT was made as the Company's PRC subsidiaries incurred tax losses for both periods.

No Hong Kong profit tax was provided for as there was no estimated assessable profit of the Group's Hong Kong subsidiary for both periods.

As at 30 June 2024, the Group had estimated unused tax losses of approximately RMB1,702,414,000 (31 December 2023: RMB1,594,145,000) which are available for offset against future profits. No deferred tax asset has been recognised in respect of the unused tax losses as at 30 June 2024 or 31 December 2023 due to the unpredictability of future profit streams.

\* English name is for identification purpose only



# Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2024

## 8. LOSS FOR THE PERIOD

	For the six months ended 30 June	
	2024 RMB'000 (unaudited)	2023 RMB'000 (unaudited)
Loss for the period has been arrived at after charging/(crediting):		
Staff costs, including directors' remuneration		
– salaries and other allowances	<b>33,486</b>	35,106
– retirement benefits	<b>3,155</b>	3,242
Total staff costs	<b>36,641</b>	38,348
Depreciation of property, plant and equipment	<b>29,067</b>	25,131
Capitalised in construction in process	<b>(129)</b>	(1,275)
	<b>28,938</b>	23,856
Amortisation of intangible assets	<b>1,311</b>	1,039
Cost of raw materials and other consumables included in research and development expenses	<b>9,829</b>	6,473
Sub-contracting costs included in research and development expenses	<b>25,664</b>	10,871

## 9. DIVIDEND

No dividends (the six months ended 30 June 2023: nil) were paid, declared or proposed during the current period. The Directors have determined that no dividend will be paid in respect of the interim period.

# Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2024

## 10. LOSS PER SHARE

The calculation of the basic and diluted loss per share attributable to owners of the Company is based on the following data:

	For the six months ended 30 June	
	2024 RMB'000 (unaudited)	2023 RMB'000 (unaudited)
Loss		
Loss and total comprehensive expense for the period attributable to: Owners of the Company	<b>(92,515)</b>	(118,114)

	For the six months ended 30 June	
	2024 Shares '000 (unaudited)	2023 Shares '000 (unaudited)
Number of shares		
Weighted average number of ordinary shares for the purpose of basic and diluted loss per share	<b>514,584</b>	514,584

For the purpose of calculation of diluted loss per share for the six months ended 30 June 2024 and 2023, the share options granted under the Pre-IPO Share Option Scheme (defined in Note 16) and the conversion of the Company's outstanding convertible bonds were not included as their inclusion would result in a decrease in loss per share.

# Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2024

## 11. PREPAYMENTS, DEPOSITS AND OTHER RECEIVABLES

	As at 30 June 2024 RMB'000 (unaudited)	As at 31 December 2023 RMB'000 (audited)
Prepayments to suppliers and service providers	<b>20,278</b>	26,581
Value added tax recoverable	<b>4,303</b>	4,334
Prepayments for purchase of property, plant and equipment	<b>36,862</b>	36,898
Advances to employees	<b>648</b>	181
Rental deposits	<b>3,719</b>	3,622
Other deposits	<b>853</b>	1,109
Others	<b>310</b>	106
	<b>66,973</b>	72,831
Analysed as:		
Non-current	<b>42,077</b>	42,113
Current	<b>24,896</b>	30,718
	<b>66,973</b>	72,831

## 12. FINANCIAL ASSETS AT FVTPL

	As at 30 June 2024 RMB'000 (unaudited)	As at 31 December 2023 RMB'000 (audited)
Investment in the Tasly Fund (Note i)	–	2,393
Investment in the Shaoxing Fund (Note ii)	<b>23,638</b>	43,969
Investment in a financial product (Note iii)	<b>10,873</b>	22,461
Investment in the certificate of deposit (Note iv)	<b>31,154</b>	102,351
Total	<b>65,665</b>	171,174
Analysed as:		
Non-current	–	46,362
Current	<b>65,665</b>	124,812
	<b>65,665</b>	171,174

# Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2024

## 12. FINANCIAL ASSETS AT FVTPL - CONTINUED

Notes:

- i. The investment represents indirect interests in a bio-science company in Korea ("**Target A**") which is accounted for as a financial asset at FVTPL under IFRS 9. As at 30 June 2024, Target A has ceased its clinical research and does not expect the research activities to be resumed in the foreseeable future, therefore, the fair value of the investment approximates to nil.
- ii. In February 2021, the Company's subsidiary, Beijing Yongtai, entered into a subscription agreement in relation to the subscription of limited partner interests in Shaoxing Yongsheng Equity Investment Partnership (LP)\* (紹興永晟股權投資合夥企業(有限合伙)) (the "**Shaoxing Fund**"). Subject to the terms of the limited partnership agreement, the initial term of the Shaoxing Fund shall be seven years and each of the partners will be entitled to share the profit or loss attributable to a project investment in proportion to their respective paid capital commitment to fund the acquisition cost of such project investment. The general partner, Tianjin Jinxin Health Technology Co., Ltd.\* (天津金新健康科技有限公司), has exclusive power over the management and control of the operation, investment affairs and other matters relating to the Shaoxing Fund.

The subscription amount of RMB50,000,000 had been paid in April 2021 and RMB24,195,000 was redeemed in June 2024. The investment was accounted for as financial assets at FVTPL under IFRS 9. The Shaoxing Fund made the investment of RMB500,000,000 to subscribe convertible bonds of a company principally engaged in gene testing services in Mainland China ("**Target B**"). The convertible bonds carry interests of 6% per annum and will originally mature in May 2024. The Shaoxing Fund may exercise its conversion option during the term of the investment and the conversion price is subject to negotiation between the Shaoxing Fund and Target B with reference to the then fair value. In March 2024, Target B early repaid RMB180,000,000 and the maturity of the remaining of the principal of RMB320,000,000 and interests are expected to be extended to May 2025. The remaining investment in the Shaoxing Fund is expected to be redeemed in the second half of 2025.

	Investment in the Shaoxing Fund RMB'000
At 1 January 2024	43,969
Redemption of the investment	(24,195)
Change in fair value	3,864
At 30 June 2024	23,638

As at 30 June 2024, the fair value of investment in the Shaoxing Fund was determined by the Directors with assistance from an independent qualified professional valuer not connected to the Group, which has appropriate qualifications and experiences in valuation of similar instruments.

The Shaoxing Fund engages in investment management, its operation purely depends on the investment it held. Its long-term investment was convertible bonds held in Target B, the fair value of the convertible bonds was determined using discounted cash flow method based on a discount rate of 44.42% per annum (31 December 2023: 12.16% or 12.86% per annum). The valuations of the remaining assets and liabilities of the Shaoxing Fund, other than long term investment, are carried out by reference to their book values.

\* English names are for identification purpose only.

# Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2024

## 12. FINANCIAL ASSETS AT FVTPL - CONTINUED

Notes: - continued

- iii. As at 31 December 2023, the Group invested in a financial product with fair value of US\$3,171,000 (equivalent to RMB22,461,000) managed by a financial institution in Hong Kong which can be redeemed at maturity in March 2024. In March 2024, the Group redeemed US\$1,701,000 (equivalent to RMB12,087,000) and continued to invest in the financial products with the remaining amount. There is no predetermined or guaranteed return for the product. Such financial products are accounted for as financial assets at FVTPL under IFRS 9.

	Investment in a financial product US\$'000	Shown in the condensed consolidated financial statements as RMB'000
At 1 January 2024	<b>3,171</b>	<b>22,461</b>
Redemption of the investment	<b>(1,701)</b>	<b>(12,087)</b>
Change in fair value (Note)	<b>56</b>	<b>499</b>
At 30 June 2024	<b>1,526</b>	<b>10,873</b>

Note: Change in fair value presented in RMB also includes the exchange effect on translation from US\$ balances into RMB.

- iv. During the year ended 31 December 2023, the Group invested in certain certificate of deposits with a bank in the PRC. The certificate of deposits carry fixed interest rate of 3.00% per annum. The Directors determine the deposits are mainly for the purpose of short-term fund management, which will be sold in the secondary market within one year, therefore the deposits are classified as current assets.

## 13. TRADE AND OTHER PAYABLES

	As at 30 June 2024 RMB'000 (unaudited)	As at 31 December 2023 RMB'000 (audited)
Trade payables	<b>52,857</b>	45,737
Payables for purchase of property, plant and equipment	<b>84,479</b>	101,552
Accrued salaries and other allowances	<b>7,524</b>	10,372
Payables for purchase of intangible assets	<b>5,783</b>	5,779
Payables for service expense	<b>9,031</b>	11,280
Notes payable	<b>2,200</b>	1,023
Others	<b>514</b>	1,168
	<b>162,388</b>	176,911

# Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2024

## 13. TRADE AND OTHER PAYABLES - CONTINUED

The following is an aged analysis of trade payables presented based on the invoice date at the end of the reporting period:

	As at 30 June 2024 RMB'000 (unaudited)	As at 31 December 2023 RMB'000 (audited)
Within 1 year	<b>38,741</b>	31,000
1 year to 2 years	<b>14,116</b>	14,737
	<b>52,857</b>	45,737

## 14. DEFERRED GOVERNMENT GRANTS

	As at 30 June 2024 RMB'000 (unaudited)	As at 31 December 2023 RMB'000 (audited)
Current	<b>710</b>	1,136
Non-current	<b>64,800</b>	38,190
	<b>65,510</b>	39,326

### Movements in deferred government grants

	Government grants related to		
	Machinery RMB'000	Research and development activities RMB'000	Total RMB'000
At 1 January 2024 (audited)	<b>38,188</b>	<b>1,138</b>	<b>39,326</b>
Government grants received	<b>30,740</b>	–	<b>30,740</b>
Release of deferred government grants to loss	<b>(4,128)</b>	<b>(428)</b>	<b>(4,556)</b>
At 30 June 2024 (unaudited)	<b>64,800</b>	<b>710</b>	<b>65,510</b>

# Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2024

## 15. OTHER FINANCIAL LIABILITIES

	30 June 2024 RMB'000 (unaudited)	31 December 2023 RMB'000 (audited)
Convertible Bonds	<b>285,791</b>	326,839

On 28 October 2022, the Company and Tasly (Hong Kong) Pharmaceutical Investment Limited (the “**Investor**”) entered into a convertible bonds subscription agreement (the “**Subscription Agreement**”), pursuant to which the Company has conditionally agreed to issue and the Investor has conditionally agreed to subscribe for the convertible bonds in the principal amount of RMB300 million. The Investor is controlled by Tasly Pharmaceutical Group Co., Ltd. (“**Tasly Pharmaceutical**”), a listed company on Shanghai Stock Exchange, both Tasly Pharmaceutical and Tasly Fund are controlled by Tasly Holding Group Co., LTD.

In February 2023, the issuance of the convertible bonds was completed and the Company received the principle amount of RMB300 million which will mature in 3 years from the date of issuance (the “**Maturity Date**”). The convertible bonds carries interests of 6% per annum and can convert into the shares of the Company at the option of the Investor at any time commencing from six months after the issue date up to the Maturity Date at the initial conversion price of RMB4.38 per conversion share subject to adjustment. If the convertible bonds are not fully converted at the Maturity Date, the Company would make up an aggregate return on the relevant principal amount of the convertible bonds of 8% per annum. The convertible bonds were secured by property, plant and equipment and financial assets at FVTPL of the Group and by the ordinary shares of the Company provided by Mr. Tan Zheng and his close family members. The convertible bonds are designated at FVTPL.

The fair value of other financial liabilities is as follows:

	Convertible Bonds RMB'000
At 1 January 2024 (audited)	<b>326,839</b>
Change in fair value	<b>(41,048)</b>
At 30 June 2024 (unaudited)	<b>285,791</b>

# Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2024

## 15. OTHER FINANCIAL LIABILITIES - CONTINUED

The fair value of convertible bonds is valued by an independent valuer using the Binomial Model. The key valuation assumptions and inputs as at 30 June 2024 to the model are as follows:

Bond maturity	1.64 years
Volatility	67.34%
Risk-free interest rate	1.59%
Discount rate for the Company	44.71%

Volatility was estimated on the valuation date based on the average of historical volatilities of the Company for a period of three years.

Risk-free interest rate was estimated based on the China government bond yield curve with similar time to maturity as at the valuation date.

## 16. SHARE-BASED PAYMENT TRANSACTIONS

Pursuant to a written resolution of the Directors on 31 December 2019, a pre-IPO share option scheme (the “**Pre-IPO Share Option Scheme**”) of the Company was approved. The Pre-IPO Share Option Scheme was established to encourage the participants to contribute to the Group for the long-term benefits of the Group. The maximum number of shares that may be granted under the Pre-IPO Share Option Scheme shall not exceed 37,500,000 shares, representing approximately 7.50% of the total number of shares in issue immediately upon completion of the IPO.

On 31 December 2019, the Company offered 7 senior managements and 25 eligible employees (collectively, the “**Grantees**”) and the Grantees accepted 37,500,000 share options (the “**Pre-IPO Share Options**”). Options may be exercised at any time from vesting date to the seventh anniversary of the date of offer.



# Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2024

## 16. SHARE-BASED PAYMENT TRANSACTIONS - CONTINUED

The details of the Pre-IPO Share Options granted to the senior management and employees of the Group are as follows:

Types	Date of offer	Number of shares subject to the option	Vesting proportion	Vesting period	Exercise price per share
Executive director: ("Share Option A") Mr. Tan Zheng	31/12/2019	5,000,000	50%	2019.12.31-2020.12.31	50% of the global offering price (the "Offer Price")
			50%	2019.12.31-2021.12.31	50% of the Offer Price
Dr. Wang Yu	31/12/2019	23,450,000	50%	2019.12.31-2020.12.31	50% of the Offer Price
			50%	2019.12.31-2021.12.31	50% of the Offer Price
Senior management: ("Share Option B")	31/12/2019	3,500,000	30%	2019.12.31-2020.12.31	50% of the Offer Price
			30%	2019.12.31-2021.12.31	50% of the Offer Price
			40%	2019.12.31-2022.12.31	50% of the Offer Price
Employees: ("Share Option C")	31/12/2019	2,550,000	50%	2019.12.31-2020.12.31	50% of the Offer Price
			50%	2019.12.31-2021.12.31	50% of the Offer Price
Employees: ("Share Option D")	31/12/2019	3,000,000	30%	2019.12.31-2020.12.31	50% of the Offer Price
			30%	2019.12.31-2021.12.31	50% of the Offer Price
			40%	2019.12.31-2022.12.31	50% of the Offer Price
Total		37,500,000			

As at 30 June 2024 and 31 December 2023, 35,930,000 options were exercisable.

## 17. CAPITAL COMMITMENTS

	As at 30 June 2024 RMB'000 (unaudited)	As at 31 December 2023 RMB'000 (audited)
Capital expenditure in respect of the acquisition of machineries, leasehold lands, leasehold improvements and the construction project contracted for but not provided in the condensed consolidated financial statements	561,406	573,993

# Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2024

## 18. FAIR VALUE MEASUREMENTS OF FINANCIAL INSTRUMENTS

Some of the Group's financial instruments are measured at fair value for financial reporting purposes. In estimating the fair value, the Group uses market-observable data to the extent it is available. Where Level 1 inputs are not available, the Group determines the appropriate valuation techniques and inputs for fair value measurements and works closely with the qualified valuer to establish the appropriate valuation techniques and inputs to the model.

Fair value of the Group's financial assets and financial liabilities that are measured at fair value on a recurring basis.

### Financial assets at FVTPL

	NOTES	Fair value as at 30/06/2024 RMB'000 (unaudited)	31/12/2023 RMB'000 (audited)	Fair value hierarchy	Valuation techniques and key inputs	Significant unobservable input	Relationship of unobservable input to fair value
Investment in the Shaoxing Fund	12	<b>23,638</b>	43,969	Level 3	Set out in Note 12	Discount rate	Note i
Investment in a financial product	12	<b>10,873</b>	22,461	Level 2	Redemption value quoted by financial institutions	N/A	N/A
Investment in the certificate of deposit	12	<b>31,154</b>	102,351	Level 2	Redemption value quoted by financial institutions	N/A	N/A

### Financial liability

Convertible bonds	15	<b>285,791</b>	326,839	Level 3	Set out in Note 15	Volatility and discount rate	Note ii
-------------------	----	----------------	---------	---------	--------------------	---------------------------------	---------

Notes:

- A slight increase in the discount rate used in isolation would result in a slight decrease in the fair value measurement of the investment, and vice versa. If the discount rate was 1.00% (31 December 2023: 1.20%) higher or lower while holding all other variables constant, the carrying amount of investment in the Shaoxing Fund would decrease by RMB143,000 (31 December 2023: RMB1,367,000) or increase by RMB145,000 (31 December 2023: RMB1,447,000) as at 30 June 2024.
- A slight increase in the discount rate used in isolation would result in a slight decrease in the fair value of convertible bonds, and vice versa. If the discount rate was 1.00% (31 December 2023: 1.00%) higher or lower while holding all other variables constant, the fair value of Convertible Bonds would decrease by RMB1,808,000 (31 December 2023: RMB536,000) or increase by RMB1,843,000 (31 December 2023: RMB555,000) as at 30 June 2024.

A slight increase in the volatility used in isolation would result in a slight increase in the fair value of Convertible Bonds, and vice versa. If the volatility was 5.00% (31 December 2023: 5.00%) higher or lower while holding all other variables constant, the fair value of Convertible Bonds would increase by RMB4,820,000 (31 December 2023: RMB5,187,000) or decrease by RMB4,866,000 (31 December 2023: RMB5,220,000) as at 30 June 2024.

# Notes to the Condensed Consolidated Financial Statements

For the six months ended 30 June 2024

## 19. RELATED PARTY TRANSACTIONS

### (a) Compensation of key management personnel

The emoluments of key management for the six months ended 30 June 2024 are as follows:

	For the six months ended 30 June	
	2024 RMB'000 (unaudited)	2023 RMB'000 (unaudited)
Salaries and other allowances	4,669	4,438
Retirement benefits	101	95
	<b>4,770</b>	4,533

### (b) Guarantee provided by related parties

As disclosed in Note 15, the convertible bonds as at 30 June 2024 was secured by Mr. Tan Zheng and his close family members. Details of the information are as follows:

	Type of pledge	Quantities '000	Fair values RMB'000
Tan Zheng Ltd	Ordinary shares of the Company	19,286	67,767
Tan Yue Yue Ltd	Ordinary shares of the Company	6,714	23,592

## Definitions and Glossary of Technical Terms

“6B11”	the monoclonal anti-idiotypic antibody prepared by Beijing Weixiao with COC166-9 immunised mice with monoclonal antibody to mimic ovarian cancer-related antigen OC166-9
“6B11-OCIK Injection”	injection of ovarian cancer autologous cytotoxic T Lymphocyte, one of the Group’s biologic product pipeline for treatment of ovarian cancer
“aT19 Injection”	aT19 Injection, the active component of the aT19 Injection product candidate is autologous T cells genetically modified to express CD19
“Audit Committee”	the audit committee of the Board
“B-ALL”	relapsed/refractory B cell acute lymphoblastic leukaemia, a type of blood cancer that usually begin in the bone marrow and result in high numbers of abnormal blood cells
“B cells”	a type of lymphocyte
“BDA”	Beijing Economic-Technological Development Area
“Beijing Weixiao”	Beijing Weixiao Biotechnology Development Limited (北京緯曉生物技術開發有限責任公司), a limited liability company established in the PRC on 15 July 2016 and owned as to 70.0% by our subsidiary Beijing Yongtai, 29.0% by Wu Shuangchen and 1% by Liao Qian
“Beijing Yongtai”	Immunotech Applied Science Limited (北京永泰生物製品有限公司), a limited liability company established in the PRC on 20 November 2006 and an indirect wholly – owned subsidiary of the Company
“Board” or “Board of Directors”	the board of directors of the Company
“CAR-T cells”	chimeric antigen receptor T cells, are T cells that have been genetically engineered to produce an artificial T-cell receptor and chimeric antigen receptors that have been engineered to give T cells the new ability to target a specific protein on the surfaces of cells
“CDE”	Centre for Drug Evaluation of the NMPA
“CDMO”	Contract Development Manufacturing Organization
“CEO”	the chief executive officer of the Company
“CG Code”	the Corporate Governance Code as set out in Appendix C1 to the Listing Rules
“China”, “Mainland China” or “the PRC”	the People’s Republic of China, excluding, for the purpose of this interim report, Hong Kong, Macau Special Administration Region and Taiwan
“CMV”	Cytomegalovirus

## Definitions and Glossary of Technical Terms

“Company” or “the Company”	Immunotech Biopharm Ltd (永泰生物製藥有限公司), an exempted company incorporated under the laws of the Cayman Islands with limited liability on 11 April 2018
“Conversion Price”	the conversion price of the Convertible Bonds, initially being HK\$4.81 per Conversion Share, equivalent to RMB4.38 per Conversion Share (based on the exchange rate of RMB1 to HK\$1.09849 which is the average mid-point daily exchange rate of RMB to HK\$ published by the People’s Bank of China for five business days prior to and excluding the date of the Subscription Agreement) (subject to adjustments)
“Conversion Shares”	the Shares falling to be allotted and issued upon the exercise of the conversion rights attaching to the Convertible Bonds
“Convertible Bonds”	the 11.75% secured convertible bonds due in 2025 in the aggregate principal amount of RMB300 million have been issued by the Company to the Investor pursuant to the Subscription Agreement
“Core Product Candidate”	our “core product” as defined under Chapter 18A of the Listing Rules, namely EAL®
“CTO”	the chief technology officer of the Company
“Denocabtagene Ciloleucel Injection”	Denocabtagene Ciloleucel injection, an injection for the treatment of patients with relapsed and refractory diffuse large B-cell lymphoma
“Director(s)”	the director(s) of the Company
“FVTPL”	Financial assets at fair value through profit or loss
“Global Offering”	the Hong Kong Public Offering (as defined in the Prospectus) and the International Offering (as defined in the Prospectus)
“GMP”	good manufacturing practice, and in the context of PRC laws and regulations, refers to guidelines and regulations from time to time issued pursuant to the PRC Drug Administration Law (中華人民共和國藥品管理法) as part of quality assurance which aims to minimise the risks of contamination, cross contamination, confusion, and errors during the manufacture process of pharmaceutical products and to ensure that pharmaceutical products subject to these guidelines and regulations are consistently produced and controlled in conformity to quality and standards appropriate for their intended use
“Group” or “the Group”	the Company and its subsidiaries
“Guosheng Laboratory”	a R&D facility located at Guosheng Technology Park, No.1 Kangding Street, Beijing Economic-technological Development Area, Beijing, China leased by the Group
“HBV”	hepatitis B Virus, a DNA virus that primarily infects the liver and can cause acute and chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma

## Definitions and Glossary of Technical Terms

“HERV-E”	human endogenous retrovirus-e antigen
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“HLA”	human leukocyte antigen, a gene complex encoding the major MHC proteins
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“IND”	investigational new drug
“Industry Fund”	the cellular immunotherapy specialised industry fund (細胞免疫治療專項產業基金)
“Investor”	Tasly (Hong Kong) Pharmaceutical Investment Limited, a wholly owned subsidiary of Tasly Pharmaceutical Group Co., Ltd., a company established in the PRC and listed on the Shanghai Stock Exchange (600535.SH)
“Korea”	Republic of Korea
“Leadman”	Beijing Leadman Biochemistry Co., Ltd, a company incorporated in the PRC, being the landlord under the Lease Agreement
“Lease Agreement”	the formal lease agreement dated 9 October 2021 entered into between Beijing Yongtai as the tenant and Leadman as the landlord in relation to the lease of the premise
“Listing” or “IPO”	the listing of the Shares on the Main Board of the Stock Exchange on 10 July 2020
“Listing Date”	10 July 2020, being the date on which the Shares were listed on the Main Board
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
“Lymphocytes”	a sub-type of white blood cells, such as T cells, B cells and NK cells
“Main Board”	the Main Board of the Stock Exchange
“MHC”	major histocompatibility complex, proteins found on the surfaces of cells specialised for displaying short peptide fragments on the surface of cells
“Model Code”	the Model Code for Securities Transactions by Directors of Listed Issuers contained in Appendix C3 to the Listing Rules
“NDA”	new drug application
“NK cells”	natural killer cells, a type of lymphocyte and a component of innate immune system
“NMPA”	National Medical Products Administration of the People’s Republic of China

## Definitions and Glossary of Technical Terms

“Poly Platinum”	Poly Platinum Enterprises Limited, a business company incorporated in the British Virgin Islands on 9 November 2018 and a direct wholly-owned subsidiary of Greater Bay Area Homeland Development Fund LP (大灣區共同家園發展基金有限合夥), an independent third party
“Prospectus”	the prospectus issued by the Company dated 29 June 2020
“R&D”	research and development
“RMB”	Renminbi Yuan, the lawful currency of China
“Reporting Period”	the six-month period from 1 January 2024 to 30 June 2024
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“Shaoxing Fund”	Shaoxing Binhai New Area Biomedical Industry Equity Investment Fund Partnership (LP)* (紹興濱海新區生物醫藥產業股權投資基金合夥企業(有限合夥))
“Share(s)”	ordinary shares with a nominal value of US\$0.001 each in the capital of the Company
“Shareholder(s)”	holder(s) of Shares
“sq.m.”	square metres
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Subscription Agreement”	the subscription agreement dated 28 October 2022 entered into among the Company, the Investor and others in relation to the subscription of the Convertible Bonds
“T cell(s)” or “T Lymphocytes”	a type of lymphocytes produced or processed by the thymus gland and actively participating in the immune response, which plays a central role in cell-mediated immunity. T cells can be distinguished from other lymphocytes, such as B cells and NK cells, by the presence of a T cell receptor on the cell surface
“T-Cure”	T-Cure Bioscience, Inc.
“Tasly Bioscience”	Tasly Bioscience Fund Limited
“Tasly Fund”	Tasly Bioscience Fund, L.P.
“TCR”	T cell receptor, a molecule found on the surface of T cells responsible for recognising fragments of antigen

## Definitions and Glossary of Technical Terms

“TGF-β”	transforming growth factor beta, a family of proteins involved in regulating and mediating processes at the cellular level
“US\$”	United States dollars, the lawful currency of the United States of America
“Yongtai Ruike”	Beijing Yongtai Ruike Biotechnology Company Ltd (北京永泰瑞科生物科技有限公司), a company established in the PRC with limited liability on 8 June 2018 and is a wholly-owned subsidiary of the Company

\* *English names are for identification purpose only.*

In this interim report, capitalised terms used shall have the same meanings as those defined in the Prospectus, unless the context otherwise requires.